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Myocarditis is a leading cause of sudden death in young adults. With its 
associated dilated cardiomyopathy (DCM), myocarditis accounts for 45% of all 
heart transplants in the United States. The mechanisms driving the 
progression of myocarditis and DCM to heart failure are largely unknown. 
The goal of my research has been to elucidate this mechanism. Increased 
interleukin-6 (IL-6) levels are associated with heart failure and are found in 
patients with DCM. The results presented in this dissertation define the 
mechanisms by which IL-6 induces myocarditis and drives dilated 
cardiomyopathy employing the mouse model of experimental autoimmune 
myocarditis (EAM). Using antibodies to the receptor of IL-6 (IL6R) and mice 
genetically deficient in IL-6 (IL-6KO), we show that IL-6 is required to induce 
EAM.  Furthermore, in experiments where IL-6KO mice were treated with 
timed doses of recombinant IL-6, we establish that there is a requirement for 
IL-6 in during the initial priming phase of EAM.  Using different adjuvant 
preparations, we establish that the main distinction between a benign 
immune response and a pathogenic immune response to the heart is partially 
due to the production of IL-6.  By interrogating chemokines and cytokines 
produced, and the cellular response in the draining lymph node, we further 
demonstrate IL-6 induces dendritic cell (DC) trafficking to the lymph node by 
DC CCR7 expression and lymph node CCL21 expression.  We then sought to 
describe the mechanism by which IL6 drives the progression of established 
EAM to DCM.  The use of anti-IL-6R antibodies established that IL-6 is 
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required for the development of DCM.  Hydrodynamic delivery of a plasmid 
encoding IL-6 to mice with EAM concluded that IL-6 drives changes in the 
functional parameters associated with heart failure while sparing further 
cardiac fibrosis.  Utilizing myocyte-restricted gp130-/- mice, GP CKO, we 
found that the requirement for IL-6 in DCM is through signaling on the 
myocyte.  We further illustrate that IL-6 signaling to the myocyte during 
DCM induces changes in the expression of proteins related to myocyte 
function, demonstrating the pathogenesis of IL-6 in DCM is attributed to 
signaling on the myocyte leading to loss of myocyte function.  Together, these 
results establish for the first time a dual role for IL-6 in EAM and DCM - first 
in the induction of an appropriate innate response during the priming phase 
of EAM and second as a direct driver of decrements in cardiac myocyte 
function.  These findings suggest that local manipulation of IL-6 levels could 
present therapeutic targets. Early targeting of IL-6 responses could be used 
to fine-tune an immune response to immunization in the context of 
vaccination.  Heart-specific targeting of IL-6 signaling during heart failure 
could potentially protect myocyte function. 
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1.1 Myocarditis: Basic Biology 
Myocarditis is inflammation of the myocardium [1].  The etiology of 
myocarditis varies from viral to bacterial to fungal to parasitic to chemical.   
Viral infection with Parvovirus 19 or Coxsackie B virus accounts for most of 
the infectious causes of myocarditis [2, 3].  Bacterial infection of Borrelia 
burgdorferi has resulted in myocarditis and, additionally, parasitic infection 
of Trypanosoma cruzi has been reported to cause myocarditis as well as heart 
dilation [2] Cardio-toxic chemicals such as 5-fluorouracil, as well as drugs 
such as doxorubicin have also been associated with myocarditis [4, 5].  
Regardless of etiology, myocarditis is the result of immune cell infiltration 
and damage to the myocardium.  Autoimmune myocarditis is hypothesized to 
develop due to the damage to the myocardium exposing auto-antigens 
combined with the already activated immune system due to infection or other 
injury to the heart [2, 6].  Some infections agents, such as Trypanosoma cruzi, 
also express foreign antigens very similar to cardiac epitopes suggesting that 
molecular mimicry may be one mechanism initiating the autoimmune 
response to the heart [7].   
The evidence for autoimmune induction in myocarditis is strong both in 
patients and animal models.  In patients, autoantibodies directed against the 
heart have been identified, CD4+ T cells have been isolated and have been 
shown to be active against heart auto-antigens and additionally, 
immunosuppressive therapy has been beneficial in patients with strongly 
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suspected autoimmune myocarditis.  Mouse models of myocarditis have been 
developed using viral induction with Coxsackie B viral infection, parasitic 
induction with Trypanosoma cruzi as well as autoimmune induction with 
myosin immunization [8-10].  The strongest animal-model evidence for the 
autoimmune induction of myocarditis comes from T cell transfer experiments, 
as myosin-reactive CD4+ T cells are sufficient to induce myocarditis [11-13].   
1.2 Myocarditis: Clinical  
Many patients with myocarditis present with general flu-like symptoms, 
which make myocarditis a difficult disease to diagnose and generally one of 
exclusion [1, 14, 15].  Other patients may not display any overt symptoms but 
succumb to sudden death and are diagnosed post-mortem [1].  Myocarditis 
can be profiled using blood tests for cardiac troponin I and creatine kinase 
MB, by echocardiography, and by cardiac MRI [2]. Endomyocardial biopsies 
are required for the gold standard of diagnosis, the Dallas Criteria, which 
defines myocarditis as the presence of mononuclear infiltration and 
cardiomyocyte necrosis upon histopathological examination of heart tissue 
[16, 17].  
Most patients that present with myocarditis will resolve their inflammation 
and will fully recover [18]. The subset of patients that do not, often develop a 
suspected autoimmune reaction to their heart leading to chronic, 
autoimmune, myocarditis [19, 20]. Autoimmune myocarditis, can be subtyped 
by biopsy, which reveals the types of immune infiltration into the heart 
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(Table 1.1).  Giant-cell myocarditis is strongly indicative of an autoimmune 
reaction and in general is highly associated with progression to heart failure 
[8, 21, 22]. Patients with eosinophilic myocarditis are at risk of rapid 
progression to heart failure or sudden death [23].  The most common sub-type 
is lymphocytic myocarditis, and still other patients will have a mixed-cellular 
infiltration. Approximately a fifth of patients with myocarditis will develop 
dilated cardiomyopathy [24].  The mechanisms driving this progression to 
heart failure are largely unknown and are the topic of the third chapter of 
this dissertation.  
1.3 Inflammatory dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is characterized by an enlarged heart that 
ultimately results in an ineffective pumping capacity and leads to heart 
failure [25]. DCM that is associated with a previous inflammatory response 
in the heart, as in myocarditis, is additionally characterized by fibrotic tissue 
[14].  Fibrosis of the heart results from remodeling of the tissue following the 
dissipation of immune cell infiltration.  DCM is the leading cause of non-
congenital cardiomyopathy in patients under the age of 40 [26].   
Treatment for patients with DCM is largely based on symptom management.  
General heart failure medications such as beta-blocks and ACE inhibitors are 
used to manage heart function [27].  There is no cure for DCM.  The only 
permanent treatment of DCM is heart transplantation and myocarditis and 
the associated DCM is the reason for approximately 45% of all heart 
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transplantation in the US [28].  For patients with a known history of 
myocarditis and suspected autoimmune associated DCM, immunosuppressive 
drugs azathioprine and prednisone have been used experimentally, with 
some success [29].  
The mechanisms driving the progression from myocarditis to DCM are 
largely unknown.  The third chapter of this dissertation will show how IL-6 
drives loss of heart function and present a potential therapeutic target, trans-
IL-6 signaling, for mediating this progression.  
1.4 Mouse models of experimental autoimmune 
myocarditis 
In order to study the biological mechanisms of autoimmune-associated 
myocarditis, we utilize a mouse model of experimental autoimmune 
myocarditis (EAM) (Figure 1.1).  EAM is an extensively characterized model 
that provides a unique tool to dissect the immune and tissue mechanisms of 
myocarditis.  EAM is induced by immunization with a peptide derived from 
the cardiac myosin heavy chain alpha (MyHCα614-629) in susceptible mouse 
strains (Figure 1.1).  BALB/c, A/J, A.SW, C3H and FVB/NF mice are all 
susceptible strains that respond to immunization. The BALB/c model has 
been most extensively characterized and will be the model of this 
dissertation.  Following immunization, mice develop robust immune cell 
infiltration into the heart staring by day 10 and peaking after 21 days.  
Subsequently, infiltration will wane and remodeling will begin.  By day 35 
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decreases in heart function can be measured and by day 45 DCM develops 
(Figure 1.2) [30]. This model provides an invaluable tool to study the 
progression of disease that mirrors the human course of disease. 
1.5 Immune cells of experimental autoimmune myocarditis 
EAM is characterized by inflammation of the myocardium with infiltration of 
immune cells into the tissue. EAM is a T-cell dependent disease [12, 13].  
Mice develop auto-reactive antibodies, however, B cells and antibodies are 
not sufficient to induce disease and do not correspond to disease severity [31, 
32]. EAM is driven by auto-reactive CD4+ T cells [12, 13]. Depletion of CD4+ 
T cells protects mice from EAM and transfer of auto-reactive CD4+ T cells 
into naïve mice induces EAM [11]. EAM will develop in the absence of any 
one subtype of CD4+ T cell, as evidenced by the use of knock-out mice which 
have a deletion in a particular lineage such as IL17AKO mice [33-36].  DCM, 
but not EAM, requires the Th17 lineage [36]. 
1.6 Interleukin-6: Basic Biology  
IL-6 is a pleiotropic cytokine which bridges the innate and adaptive immune 
systems [37]. Perturbations or dysfunction in the transition from innate to 
adaptive immunity have long term consequences for inflammation and 
autoimmunity [38]. The acute response to IL-6, which is largely protective, to 
chronic, long term signaling leading to pathogenic inflammation and 
autoimmunity is an example of the varying faces of IL-6 [39].   
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IL-6 has a wide array of biological functions and is produced by many cells of 
the body.  Originally identified as a B-cell differentiation factor, IL-6 is now 
recognized as a cytokine that regulates many processes such as the acute-
phase response, inflammation and hematopoiesis. It can be made by most 
tissues as well as virtually all cells of the immune system.  IL-6 can signal 
either through membrane-bound receptors or, uniquely within the IL-6 
family of cytokines, can signal in trans, with a soluble form of its receptor 
(Figure 1). IL-6 has been shown to participate in neurogenesis, wound 
healing and hepatic regeneration [40-42].  Acutely, IL-6 responds to almost 
all perturbations of homeostasis. However, when IL-6 remains elevated 
chronically, the protective roles of IL-6 in maintaining tissue integrity and 
signaling in the immune response are no longer required and constant 
signaling becomes associated with fibrosis and chronic inflammation. This 
dual role of IL-6, from acute and beneficial to chronic and harmful, is the 
subject of this dissertation.   
IL-6 specific biologic functions and signaling 
IL-6 is a member of the IL-6 family of cytokines that also includes IL-11, IL-
31, cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), cilliary 
neurotrophic factor (CNTF) leukemia inhibitory factor (LIF), neuropoietin 
(NPN), and oncostatin M [43-45].  
As a multi-functional cytokine, IL-6 acts on the immune system as well as 
other local tissues.  Within the immune system, IL-6 can direct the 
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development and activation status of both innate and adaptive immune cells.  
IL-6 signaling up-regulates anti-apoptotic molecules in T cells [46-48]. In 
addition, IL-6 is required for Th17-lineage differentiation through STAT3 
dependent mechanisms [49, 50]. This is particularly important because the 
Th17 lineage has been implicated as a contributor to pathogenesis in many 
autoimmune diseases. IL-6 also has functions in the innate immune system, 
where it induces the differentiation of monocytes to macrophages rather than 
dendritic cells [51]. IL-6 may also influence DC activity as it can alter DC 
CCR7 expression and IL-6 secretion by DCs can affect the 
immunosuppressive activity of Tregs [52-54], thus bridging the innate and 
adaptive immune responses. And importantly for the initiation of many 
inflammatory responses, in the tissue IL-6 suppresses neutrophil infiltration 
while promoting directed trafficking and activation of mononuclear 
leukocytes [55-59]. Together, these studies show how IL-6, if not properly 
controlled, can direct a proinflammatory immune response that can trigger 
an auto-aggressive response through the Th17 lineage. 
The IL-6 cytokine family signals through a cytokine-specific receptor 
complexed with at least one subunit of the signal-transducing protein, gp130 
[44]. IL-6 specifically signals through a complex of the IL-6R (also known as 
IL-6R-alpha) [60] and the IL-6-family common receptor gp130 [61, 62].  
GP130 signaling mediates a variety of cellular processes including cell 
survival, apoptosis, growth, proliferation, differentiation and survival [63-66]. 
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GP130 is part of the receptor complex for CNTF in the brain, LIF, oncostatin 
M, NPN, cardiotrophin (CT-1), IL11, IL27 and IL31 [67-73]. Importantly, 
gp130 is expressed on nearly all cells in the body.  Therefore, what gives IL-6 
family cytokines tissue-specificity is the cellular expression of the co-receptor 
for each family member cytokine. 
The IL-6R is mainly expressed on hepatocytes and immune cells. However, 
IL-6 is unique in the IL-6-family because it has a soluble form of its receptor.  
Therefore, cells lacking the IL-6R can still respond to IL-6 because the 
naturally occurring soluble form of the IL-6R exists and can create a complex 
with IL-6 (Figure 1.3). IL-6 first binds to the IL-6R and this complex of IL-6 
and IL-6R then binds with gp130 [74, 75]. The soluble IL-6R (sIL-6R) is 
generated either by cleavage of the membrane-associated receptor or, 
independently, by translation of an alternatively spliced mRNA [76-78]. This 
signaling of the sIL-6R and the membrane bound gp130 is referred to as IL-6 
trans-signaling [79] (Figure 1.3). Trans-signaling has been shown to be active 
in many systems where cells only become responsive to IL-6 in the presence 
of the sIL-6R, such as in hematopoietic progenitor cells [80, 81], T cells [82, 
83], and endothelial cells [84]. 
Downstream signaling of the IL-6R combined with gp130, whether soluble or 
membrane bound, signals through JAK-STAT, Ras-MAPK, or PI3K, 
pathways [85, 86]. Within the JAK-STAT pathway, IL-6 specifically signals 
through STAT3, which dimerizes and then translocates to the nucleus [87]. 
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Regulation and termination of downstream IL-6 signaling is mediated 
through suppressor of cytokine signaling (SOCS) proteins [88-90]. The 
negative regulator of IL-6-STAT3 activation, SOCS3, may in part regulate 
the protective versus pathogenic effects of IL-6.   
1.7 The role of interleukin 6 in cardiac inflammation and 
cardiac failure in humans 
Population based studies 
Meta-analysis of human studies has demonstrated that long-term elevation 
of IL-6 levels more than double a person’s life-time risk of coronary heart 
disease [91]. These studies, among many others, demonstrate an association 
between pathology and chronic IL-6 levels. Recent studies have established a 
causal role of increased IL-6R protein levels in coronary heart disease (CHD) 
[92-94].  Not understood, is whether elevated IL-6 was a byproduct of the 
cardiovascular disease (CVD) or was serving a pathogenic function. Whereas 
association studies have suggested that long-term elevation of IL-6 levels 
have adverse consequences for cardiac health, these 2 studies have finally 
given clear evidence that IL-6, a proinflammatory cytokine, plays a causal 
role in determining CVD risk (Table 1.2). The studies focused on a genetic 
variant in the population that is associated with increased IL-6 levels 
circulating in the blood, but decreased IL-6R signaling. Interestingly, these 
groups went on to look at the effect of the variant compared to the anti-IL-6R 
drug, tocilizumab, and found that the variant was associated with the same 
biological changes as the inhibiting drug.  The findings of these studies 
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suggest that targeting IL-6 or, in particular IL-6R-mediated signaling, may 
be a possible therapeutic intervention for CVD, including a possible 
preventative measure in high risk individuals. 
On a population level, the many polymorphisms in the IL-6 promoter region 
as well as polymorphisms in the IL-6R gene locus are associated with 
inflammation and increased disease risk [95-98].  A particular polymorphism 
in the promoter region of IL-6 was shown to lead to higher systemic levels of 
IL-6 [95-97]. This variant is uniquely associated with susceptibility to 
systemic juvenile idiopathic arthritis and importantly, led to the use of anti-
IL-6R antibody for its treatment [98-101]. The polymorphisms associated 
with elevated protein levels of IL-6R are also associated with inflammation 
and are predictive of adverse coronary outcomes such as cardiovascular 
disease [93] and abdominal aortic aneurism [102]. Elevated IL-6 serum levels 
in patients may be predictive of poor outcomes, thus providing a potential 
prognostic tool, in a variety of heart-related diseases such as heart failure, 
myocardial infarction (MI), and angina [103-106]. Human studies clearly 
implicate IL-6 signaling in the heart to be pathogenic over time, however 
some experimental data using animal models of acute insult to the heart, 
contradict these associations.  The final outcome of IL-6 signaling seems to be 
greatly dependent the duration of the signaling, as well as the downstream 
signaling cascades activated. 
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The identification and description of IL-6 trans-signaling has begun to 
explain how IL-6, uniquely in the IL-6-family, has been shown to be 
protective in acute inflammation and disease such as septic shock but 
pathogenic in chronic disease [107-111]. Early in the study of IL-6, chronic 
overproduction of the cytokine was implicated in the pathogenesis of many 
inflammatory conditions including rheumatoid arthritis (RA), Castleman’s 
disease and cardiac myxoma [112-114]. In all these disease states, a 
constitutively increased IL-6 level explained the pathogenic inflammatory 
symptoms of the patients.   Because of this, a therapeutic antibody targeting 
IL-6 signaling, anti-IL-6R, which targets membrane-bound as well as a 
soluble receptor, has been used to treat RA in small studies of Castleman’s 
disease and multiple myeloma [115-117]. Targeting the IL-6R has been 
shown to be particularly effective in clinical trials for severe RA [118-120] 
and Crohn’s disease [121] which is important because IL-6 trans-signaling is 
particularly implicated in these diseases where high levels of sIL-6R have 
been found in patients [122-125] and associate with worse disease outcomes 
[125].  Trans-signaling of IL-6 may be more common in chronic IL-6 
pathology and thus a way to target chronic signaling in the long-term, while 
preserving classical IL-6 signaling, which is required during acute tissue 
insult. 
IL-6 in mouse models of inflammatory disease 
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IL-6 is pathogenic in a variety of inflammatory conditions in mouse models 
(Table 1.3). IL-6KO mice are resistant to experimentally induced RA [126], 
colitis [82], experimental autoimmune encephalitis (EAE) [127], experimental 
autoimmune myocarditis (EAM) [128] and autoimmune kidney disease [129]. 
Additionally, antibodies that target IL-6 signaling block the development of 
many of these same diseases. IL-6R blockade ameliorates colitis [82], inhibits 
the onset of autoimmune kidney disease [130] and delays the development of 
collagen induced arthritis [131]. How exactly IL-6 is exerting its effects in 
each model may show a role for signaling both to the immune system as well 
as the local affected tissue.  
Evidence for the role of local, tissue-specific IL-6 signaling in the 
pathogenesis of chronic inflammatory diseases comes from mouse studies 
that specifically target IL-6 trans-signaling. The argument can be made that 
whole-animal knockouts of IL-6 or systemic blockade of IL-6 have many 
effects and thus the specific role that IL-6 is contributing cannot be teased 
away from these off-target effects.  However, by targeting trans-signaling, 
classical IL-6 signaling is preserved, therefore only cells that do not express 
the IL-6R are impacted.  In many studies this translates into the local 
blockage of IL-6 signaling in the tissue by blocking IL-6 trans-signaling as 
immune cells have the IL-6R. In one study of renal pathology in lupus-prone 
mice, an inhibitor of trans-signaling, sgp130Fc was overexpressed in Lyn-
deficient mice and its effect on lupus-associated pathology was measured. IL-
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6-deletion in Lyn-deficient mice leads to decreased inflammation, decreased 
autoantibodies and decreased nephritis [132].  In the sgp130Fc mice, that 
have classical IL-6 signaling but lack trans-signaling, there was no changes 
in immune cells, however, there was significantly attenuated 
glomerulonephritis and improved renal function and reduced complement 
fixation, showing a role for IL-6 in the local kidney response [132]. Additional 
studies support these findings in other mouse models. It has long been known 
that IL-6KO mice do not develop RA [133] but further studies have shown 
that targeting IL-6 trans-signaling ameliorates RA [134]. Methods to target 
the local response to IL-6 have been developed, such as tissue-restricted IL-6 
production where the whole animal is an IL-6KO except for a tissue of 
interest.  CNS-specific production of IL-6 in a mouse model of EAE showed 
that IL-6 production in the brain increases inflammatory cell infiltration 
impairs the blood-brain barrier and worsens disease outcome [135]. 
Collectively, these studies demonstrate a powerful, pathogenic role of IL-6 in 
the local tissue that potentially can be therapeutically targeted through the 
sIL-6R. 
IL-6 in the Heart  
The cellular response to IL-6 in the heart has been well characterized.  
Cardiac tissue provides a revealing example where the duration of signaling, 
from acute to chronic, demonstrates the protective and pathogenic transition 
(Figure 1.4).   
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IL-6 family signaling to cardiac myocytes is cardio-protective during the 
acute response; however, when IL-6 remains elevated chronically, it induces 
maladaptive hypertrophy and decreases contractile function [136, 137]. 
Myocytes themselves make IL-6 in response to injury and in addition to 
increased IL-6 signaling, increased IL-6 production is associated with 
depressed cardiac function [138].  Acutely, IL-6-family cytokines protect 
myocytes against oxidative stress and its signaling induces an anti-apoptotic 
program [137, 139, 140]. However, IL-6-family signaling also depresses the 
basal contractility of the myocytes as well as the beta-adrenergic 
responsiveness of the cells leading to decreased function [141]. Prolonged IL-6 
family signaling also induces gene expression in the myocytes that is 
associated with pathological hypertrophy [136]. In chronically IL-6 exposed 
myocytes, the depressive effects on contractility of IL-6 are mediated by 
enhancing de novo synthesis and activation of calcium-independent iNOS 
proteins [142]. Interestingly, the IL-6-driven decrease in contractility was 
associated with JAK/STAT signaling but not the alternative downstream 
signaling, ERK pathway, suggesting that differential regulation of 
downstream signaling is a factor in fine-tuning the cellular response to IL-6-
family signaling [142]. 
The most well characterized protective functions of IL-6 family signaling 
have been studied in ischemia-reperfusion injury and myocardial infarction 
which both induce IL-6 production by cardiac myocytes [143-147].  Increased 
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IL-6 plays a role in late phase pre-conditioning that confers cardio protection 
[148, 149]. STAT3, the downstream signaling molecule of IL-6, is also 
required for pre-conditioning [148]. However, chronic elevated myocardial 
production of IL-6-family cytokines, which occurs post-MI and in HF, have 
been associated with worse heart outcomes [137, 139, 150].  IL-6 is 
consistently upregulated in the infarct zone after experimental MI and is 
associated with left ventricle (LV) enlargement [145, 151, 152]. It is thought 
that the combined acute effects of IL-6, anti-apoptosis, depressed contractility 
and hypertrophy, will lead to preserved myocardium in the infarct border 
zone [145]. Thus, the deleterious effects of IL-6 chronically serve a protective 
function in MI.  Acutely, the combined effects of IL-6 production and 
signaling by the myocytes leads to preserved cardiac tissue, where damage is 
limited by reducing the contractility of the cells and inducing an anti-
apoptotic program.  In the short term these changes lead to smaller infarct 
zones and thus acute IL-6 is protective in MI.  However, both mouse and 
human studies showed that when this elevated IL-6 continues past the initial 
requirement to preserve the insulted tissue, these same effects become 
deleterious.  By inducing an anti-apoptotic program and reducing 
contractility in the long-term, the tissue is less effective as a muscle and 
begins to induce a genetic program related to hypertrophy, which can 
ultimately result in heart failure. Thus continued IL-6 signaling is 
pathogenic.  
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IL-6 signaling has also been studied from the perspective of limiting or 
terminating signaling. In cultured cardiac myocytes, overexpression of 
SOCS3 (limiting IL-6-family signaling) completely suppresses the ability of 
the IL-6-family cytokines to be anti-apoptotic and induce hypertrophy [153]. 
This is mirrored in human data where a decrease in myocardium SOCS3 
protein expression, which would lead to continuous IL-6 signaling, has also 
been found in the LV of patients with DCM [154]. Fine-tuning the signal 
cascade of IL-6 may solve the apparent discrepancy of high IL-6 levels 
associating with poor heart outcomes, but experimental evidence shows 
gp130 signaling to be cardio protective. In a mouse model of MI, high levels of 
IL-6 increased adverse LV remodeling and heart failure because of impaired 
regulation of the downstream signaling of IL-6, leading to pathogenic, 
sustained gp-130-mediated STAT3 activation [155]. This study was 
particularly instructive because the authors identified that signaling through 
the tyrosine-757 residue on the gp130 receptor mediated these outcomes and 
lead to prolonged and enhanced JAK/STAT activation, without ERK and Akt 
signaling, thus pinpointing a specific cascade [155].  The identification of a 
specific downstream signaling cascade is an important goal because it may 
identify how or why acute IL-6 is not properly regulated and instead shifts to 
a chronic signal. 
In the myocardium, both chronically elevated IL-6 and increased IL-6R 
expression lead to continuous activation of gp130, which results in 
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hypertrophy [140, 156]. To identify the role that STAT3 signaling plays in 
pathogenic IL-6 signaling, mice were created that over-express STAT3 in the 
heart. Mice with a cardiac-specific increase in expression of STAT3, the 
downstream signaling target of the IL-6 cytokines, develop hypertrophy 
without stimuli [157]. This demonstrates that uncontrolled, continuous 
STAT3 signaling causes pathogenic changes in the myocardium, independent 
of initial tissue insult. Alternatively, complete loss of the myocyte expression 
of gp130 (through cardiac-specific knockout) results in a heart with normal 
structure and function, although the heart is susceptible to cardiac myocyte 
apoptosis and dilation in response to pressure-overload [158]. This illustrates 
the need for IL-6 in the acute response to injury in order to prevent the 
progression of compensatory LV hypertrophy to heart failure [159]. 
IL-6 in Myocarditis 
Myocarditis provides a striking example of how the dysregulation of normally 
protective IL-6 responses leads to a pathogenic outcome.  During the acute 
stage of a virus onvection, IL-6 is protective in the heart as it limits viral 
replication and thus cardiac damage [160].  However, once the virus has been 
cleared a subset of patients will eventually develop an autoimmune response 
to their heart and present with autoimmune myocarditis, independent of 
viral presence [8].  Many of these cases are associated with continuous IL-6 
signaling.  Over time, patients with autoimmune myocarditis may develop 
dilated cardiomyopathy, which at its end-stage can only be treated with a 
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heart transplant [8]. Circulating serum levels of IL-6 increase with the 
severity of heart failure [161, 162] and upon autopsy, IL-6 has been found to 
be increased in the heart tissue of patients with DCM [163, 164] and end-
stage heart failure [162, 165, 166].  Myocarditis is an extreme example of how 
limited acute IL-6 signaling is protective for viral clearance but the chronic, 
long term exposure of the heart to IL-6 contributes to pathology and loss of 
cardiac function and remodeling. This dissertation will demonstrate the 


















1.8 Figures and Tables 
 
Figure 1.1. Induction of experimental autoimmune myocarditis 
(EAM)  
To induce EAM, male BALB/c mice at 6-8 weeks of age, are immunized the 
myocarditogenic peptide of cardiac myosin heavy chain, MyHC 614-629 (Ac-
SLKLMATLFSTYASAD) emulsified in CFA. On days 0 and 7, mice received 
an axillary subcutaneous immunization of 100 g of MyHC 614-629 peptide 
emulsified in CFA supplemented to 5 mg/mL of heat-killed Mycobacterium 
tuberculosis strain H37Ra. On day 0, mice additionally received 500 ng of 
pertussis toxin intraperitoneally. On day 10 following immunization immune 
cells begin to infiltrate the myocardium.  Day 21 is peak of inflammation, 






Figure 1.2. Induction of dilated cardiomyopathy 
To induce DCM, male BALB/c mice at 6-8 weeks of age, are immunized the 
myocarditogenic peptide of cardiac myosin heavy chain, MyHC 614-629 (Ac-
SLKLMATLFSTYASAD) emulsified in CFA. On days 0 and 7, mice received 
an axillary subcutaneous immunization of 100 g of MyHC 614-629 peptide 
emulsified in CFA supplemented to 5 mg/mL of heat-killed Mycobacterium 
tuberculosis strain H37Ra. On day 0, mice additionally received 500 ng of 
pertussis toxin intraperitoneally. On day 10 following immunization immune 
cells begin to infiltrate the myocardium.  Day 21 is peak of inflammation and 
EAM.  By day 35, heart function begins to decrease as measured by 
echocardiography.  By day 45 hearts are enlarged and DCM is apparent by 






Figure 1.3. IL-6 trans-signaling 
IL-6 has the ability to signal to cells that lack the membrane-bound IL-6R. 
IL-6 can bind with the soluble-IL-6R, which in turn will bind with 
membrane-bound gp130 to form a signaling complex.  This soluble-receptor 
signaling is termed ‘trans’-signaling as opposed to the membrane-bound IL-




Figure 1.4. Acute and Chronic IL6 signaling in the myocyte 
The figure depicts transition from acute, protective IL6 signaling, to chronic, 
pathogenic IL6 signaling on the cardiomyocyte. In the acute phase (on the 
left), IL6 preserves cardiac tissue by inducing an anti-apoptotic program in 
the myocyte and triggers the pre-conditioning response.  When IL6 signaling 
continues chronically, these protective responses become pathogenic and 
induce depressed myocyte function (on the right).  There is decreased 




Table 1.1 Subtypes of Human Myocarditis 
Subtypes of Immune-cell infiltration during Myocarditis in Human 
Infiltration 
Type 
Likely etiology Outcome 
Giant-cells Autoimmune Heart failure 





























Table 1.2. The dual role of IL-6 in human studies  
 Beneficial Harmful 
Acute signaling   
Elevated IL-6 serum 
levels in patients with 
myocarditis 
Limits viral infection 
[160] 
Associated with DCM 
[163] 
Elevated IL-6 serum 
levels following 
myocardial infarction 
Limits infarct size 
[148, 149] 
Associated with HF and 
LVF[167] 
Chronic signaling   
Long-term elevated IL-6 
serum levels 
 Two fold Increased life-
time risk of CHD [4] 
Long-term elevated sIL-
6R serum levels 
 Associated with severe 
RA [118, 119] 
Polymorphism in IL-6R 
leading to elevated IL-
6R protein expression in 
sera 
 Increased susceptibility 
to systemic juvenile 
idiopathic arthritis 
(SJIA) [98] 
Predictive of adverse 
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Table 1.3. The dual role of IL-6 in mouse model studies  
 Beneficial Harmful 
Acute signaling   
Increased myocyte 












LV enlargement [145, 
151, 152] 











Chronic signaling   
Myocyte-specific gp130 
loss 
No IL-6 signaling [125] Susceptible to myocyte 
apoptosis in pressure-
overload models [158] 
Cardiac-specific 







IL-6KO mice  Resistant to 
experimentally induced 
RA [96], colitis [87], 



















Chapter II: Interleukin 6 is required for the 























The precise role IL-6 plays in the induction of EAM is unknown.  Earlier 
studies have shown that IL-6 is required for disease induction, as IL-6KO 
mice do not develop EAM.  However, why IL-6 is required remains unclear.  
The objective of these experiments was to define the role of IL-6 in EAM.  We 
hypothesized that IL-6 was required for the initial induction of EAM based on 
preliminary data showing that IL-6 levels were significantly elevated 
following immunization.  The aims of this research were to first define the 
timeframe in which IL-6 was required to induce disease and second, to 
describe the mechanism of action of IL-6 in EAM induction.  
2.2 Results 
Mice treated with anti-IL-6-receptor antibodies are protected from 
EAM 
In order to study the role that IL-6 plays in the pathogenesis of EAM in the 
standard mouse model, we employed an anti-IL-6-receptor blocking antibody 
(Figure2.1A-E). Wild-type (WT) BALB/c mice were treated with an anti-IL-6R 
antibody or isotype control and then immunized with the MyHCα614-629 
peptide emulsified in CFA. At 21 days post immunization, cardiac 
histopathology analysis revealed that mice receiving the anti-IL-6R antibody 
were protected from EAM, whereas IgG2a treated controls developed EAM 
(Figure 2.1A-B). Flow cytometric analysis demonstrated that there were 
significantly increased numbers of CD45+ leukocytes in the hearts of control 
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compared to anti-IL-6R treated mice (Figure 2.1C). Anti-IL-6R treatment 
raised the systemic circulating levels of IL-6 (Figure 2.1D), but IL-6R 
downstream signaling, as measured by the levels of pSTAT3 in heart 
homogenates at day 21, was significantly reduced (Figure 2.1E) confirming 
the efficiency of the IL-6R blocking antibody.  
Systemic IL-6 levels increase following immunization with CFA 
To isolate the timeframe in which IL-6 is required during EAM, systemic IL-6 
levels were profiled during the course of disease as well as in response to CFA 
specifically.  WT BALB/c mice were immunized with MyHCα614-629 peptide 
emulsified in CFA at day 0 and 7 and blood was drawn on the days 0, 3, 10, 
15, 21 (Figure 2.2A). Over the course of disease, IL-6 was maintained at 
elevated levels in the serum.  Although IL-6 levels decreased in the serum 
after day 10, serum levels were significantly elevated compared with baseline 
values (Figure 2.2A).  In order to distinguish the IL-6 response to CFA versus 
CFA + peptide in the emulsion, mice were immunized either with CFA alone 
(Mock) or CFA with the MyHCα614-629 peptide on day 0. On day 3 post-
immunization, there was no significant difference between the IL-6 response 
to CFA alone and CFA + peptide indicating that, at this early time point, the 
IL-6 increase is independent of peptide presence in the emulsion (Figure 
2.2B).  Therefore, the IL-6 increase in the inductive phase of the response 
does not require the presence of the myosin antigen.  
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Recombinant IL-6 treatment partially restores susceptibility to EAM 
in IFA immunized mice 
CFA is required for the induction of EAM. IFA induces an antibody response 
without inducing infiltration into the heart and subsequent lesions and 
disease. In order to ascertain whether the difference between a pathogenic 
versus inert response to immunization was related to the production of IL-6, 
we immunized mice with IFA or CFA with or without recombinant IL-6.  WT 
BALB/c mice were immunized with MyHCα614-629 peptide emulsified in 
either IFA or CFA at day 0 and 7 (Figure 2.3).  In addition to the 
immunization, mice were either injected with 50 ng of recombinant IL-6 IV at 
the time of immunization (Figure 2.3).  Mice were then sacrificed 21 days 
post-immunization. Histopathology of mouse hearts showed that mice 
immunized with IFA alone were protected from heart inflammation, whereas 
mice immunized with CFA developed heart inflammation (Figure 2.3).  In 
contrast, mice immunized with IFA and treated with recombinant IL-6 at the 
day 0 immunization developed infiltration in the heart. This finding 
demonstrates that recombinant IL-6 treatment restores partial susceptibility 
to EAM in otherwise EAM-resistant mice.  Therefore, IL-6 is partially 
responsible for the difference between a pathogenic and an inert response in 
the heart in response to immunization.  
IL-6 is only required for the initial response to immunization in 
order to induce EAM 
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IL-6 is required for the development of EAM (Figure 2.1) IL-6 is also 
important for the response to adjuvant in inducing pathogenic responses 
against the heart (Figure 2.3).  We then wanted to identify the critical 
window in which IL-6 is absolutely required for disease induction.  It has 
been reported that IL-6KO mice are completely resistant to EAM [170].  To 
identify the precise role IL-6 plays in the development of EAM, we treated IL-
6KO mice with PBS or recombinant IL-6 in order to compare their disease 
development with WT mice.  WT BALB/c or IL-6KO BALB/c mice were 
immunized with MyHCα614-629 peptide emulsified in CFA at day 0 and 7.  
On days -1,0,1,2 mice were treated with either PBS or 50 ng recombinant IL-
6 IV (Figure 2.4A).  Histopathology of mouse hearts showed that IL-6KO mice 
receiving recombinant IL-6 developed heart inflammation comparable to WT 
mice (Figure 2.4B).  Therefore, we have established that IL-6 during the 
inductive phase is sufficient to drive EAM.    
IL-6 leads to differential DC profiles in the draining lymph node 
following immunization 
In order to more precisely define the role IL-6 plays in response to 
immunization, we studied the DC response in the lymph nodes draining the 
immunization site.  BALB/c mice were immunized in the hind limb at day 0 
and sacrificed 3 days post-immunization. Flow cytometric analysis showed 
that mice treated with anti-IL-6R antibodies had significantly lower levels of 
CD11c+ DCs in the draining lymph nodes of the sites of immunization 
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(Figure 2.5A). These DCs had lower expression of maturity marker MHCII 
expression but similar levels of CD8+ expression compared to untreated mice 
(Figure 2B and data not shown).  Therefore, IL-6 appears to be important for 
the DC response in the draining lymph nodes that is associated with the 
induction of EAM.  
IL-6 induces DC migration to the draining lymph node through DC 
CCR7+ expression and LN CCL21 expression 
To further identify whether IL-6 induced DC maturity or trafficking, we 
investigated the trafficking markers of the DCs and the draining lymph 
nodes.  BALB/c mice were immunized in the hind limb and sacrificed 3 days 
post-immunization.  The draining lymph node of the immunization site was 
collected. Lymph node cytokine and chemokine levels were interrogated by 
ELISA and Multiplex cytokine bead array.  DC populations were interrogated 
by flow cytometry.  Interestingly, the levels of LN trafficking marker, CCR7, 
showed a decrease in the anti-IL6R treated animals (Figure 2.6A).  We also 
investigated the ligand of CCR7, CCL21 expression in the draining lymph 
node.  Using the same experimental design, we isolated the draining lymph 
nodes and homogenized the whole lymph node. Mice treated with anti-IL-6R 
antibodies had lower expression of CCL21 (Figure 2.6B). Cytokine and 
chemokine production in the draining lymph node showed that there were 
few statistically significant changes, however, there was a trend that DC-
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related trafficking markers were decreased in mice treated with anti-IL6R 
antibodies (Figure 2.7). 
 Together, these experiments illustrate that IL-6 is required for DC 
trafficking to the draining lymph node through the upregulation of CCR7 on 
the DC as well as increased expression of CCL21 by cells of the draining 





















In these experiments, we have altered the systemic levels of IL-6 during EAM 
induction in WT BALB/c in order to demonstrate the requirement of IL-6 in 
EAM induction. Using anti-IL-6R antibodies we have shown that IL-6 is 
necessary for EAM induction.  Further, using IL-6KO mice and recombinant 
IL-6 treatment, we have determined that the necessity for IL-6 is only during 
the days surrounding the initial CFA immunization. It has previously been 
shown that IL-6KO mice do not develop disease [170].  We have clarified this 
finding, demonstrating that the requirement for IL-6 is not throughout the 
course of EAM, but rather specifically for the immune response to 
immunization.  Additionally, we have elucidated the role IL-6 plays in 
response to adjuvant. It is known that IFA immunization does not induce 
organ-specific autoimmune disease in the mouse, and CFA is required for 
disease induction [171].  In EAM, IFA induces an auto-antibody response 
without inducing a pathogenic T cell response leading to heart lesions. We 
have demonstrated that one of the driving immunologic responses to 
adjuvant is the production of IL-6.  Mice treated with recombinant IL-6 on 
the day of IFA immunization developed a low but detectable level of heart 
infiltration not previously seen under these challenge conditions.  
To determine the mechanism by which IL-6 exerts its effects in the 
development of an immune response to adjuvant, we used antibody treatment 
to block IL-6R signaling.  On days -3 and day 0 of immunization we treated 
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WT BALB/c mice either with isotype control antibodies or antibodies directed 
against the IL-6R.  This established mice that either had IL-6 signaling 
abilities, or did not, with the additional benefit of mice that biologically 
developed with IL-6 competence as compared with IL-6KO mice.  Three days 
following immunization we interrogated the immune response by multiple 
methods.  Cellular populations in the draining lymph node of the 
immunization site were analyzed by flow cytometry. Through this extensive 
characterization of the IL-6-induced immune response to adjuvant, we 
demonstrated that anti-IL-6R treatment resulted in fewer DCs in the 
draining lymph node, with lower expression of maturation marker MHCII 
and trafficking marker CCR7. We also demonstrated that anti-IL-6R 
treatment lowered the lymph node expression of inflammatory DC chemokine 
CCL21. Other changes in chemokine and cytokine production in the draining 
lymph node were mild, but supported the induction of mediators of 
inflammatory trafficking of cells to the lymph node.  Thus, we have shown 
that in response to immunization, IL-6 induces DC CCR7-CCL21 mediated 
trafficking to the draining lymph node. This difference in DCs in the draining 
lymph node is also accompanied by upregulation of maturity marker MHCII 
by the DCs. 
Through these experiments we have elucidated fundamental mechanisms by 
which IL-6 induces innate response to adjuvant. IL-6 is required for initial 
DC responses that ultimately lead to the difference between an inert 
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immunological response without IL-6, versus a robust immunological 
response, with IL-6.  
2.4 Materials and Methods 
Mice 
WT BALB/cJ and IL-6-/- BALB/c mice were purchased from the Jackson 
Laboratory. All mice were maintained in the Johns Hopkins University 
School of Medicine specific-pathogen free vivarium. Experiments were 
conducted on 6-8 week old male mice, in compliance with the Animal Welfare 
Act and the principles set forth in the Guide for the Care and Use of 
Laboratory Animals. All methods and protocols performed were approved by 
the Animal Care and Use Committee of The Johns Hopkins University. 
Induction of EAM 
To induce EAM, we employed the myocarditogenic peptide of cardiac myosin 
heavy chain, MyHCα614-629 (Ac-SLKLMATLFSTYASAD). The peptide was 
commercially synthesized by fMOC chemistry and purified to a minimum of 
90% by HPLC (Genscript). On days 0 and 7, mice received an axillary 
subcutaneous immunization of 100 μg of MyHCα614-629 peptide emulsified 
in either complete Freund’s adjuvant (CFA) (Sigma) supplemented to 5 
mg/mL of heat-killed Mycobacterium tuberculosis strain H37Ra (Difco) or 
incomplete Freund’s adjuvant (IFA) (Sigma). On day 0, mice additionally 
received 500 ng of pertussis toxin intraperitoneally. (List Biologicals).   
 36 
Anti-IL-6R Treatment 
Wild-type (WT) BALB/c mice were divided into 2 groups of 8 mice each; 
treatment with an anti-IL-6R antibody (BioXcell) or isotype control, IgG2b 
(BioXcell).  Antibody treatment was given IV at day-7 (1 mg) and day 0 (0.5 
mg) of the immunization protocol. These mice were then immunized with the 
MyHCα614-629 peptide emulsified in CFA and sacrificed 21 days post-
immunization. 
Assessment of EAM Histopathology 
Mouse hearts were evaluated for the development of EAM on day 21. Heart 
tissues were fixed in SafeFix solution (Fisher Scientific). Tissues were 
embedded in a paraffin block in a longitudinal orientation and 5 μm serial 
sections were cut and stained with hematoxylin and eosin (H&E) (HistoServ, 
Gaithersburg, MD). Myocarditis severity was evaluated by visually 
estimating the area of the myocardium infiltrated with hematopoietic cells 
using the published scoring system: grade 0, no inflammation; grade 1, less 
than 10% of the heart section is involved; grade 2, 10-25%; grade 3, 25-50%; 
grade 4, 50-75%; grade 5, more than 75%. Grading was performed by grading 
sections per heart by two independent, blinded investigators and the values 
were expressed as an average.  
Flow Cytometry Analysis and FACS Isolation of Heart Infiltrating 
Cells 
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To prepare the cellular infiltrating populations for flow cytometry analysis, 
single cell suspensions were made from mouse hearts.  Hearts were perfused 
for 3 min with 1x phosphate buffered saline (PBS) + 0.5% FBS, and digested 
in GentleMACS C Tubes according to manufacturer’s instructions (Miltenyi 
Biotec). Viability was determined by LIVE/DEAD staining according to 
manufacturer’s instructions (Life Techonologies). Cells were blocked with 
αCD16/32 (eBiosciences), and surface markers were stained with 
fluorochrome-conjugated mAbs (eBioscience, BD Pharmingen, BioLegend). 
Samples were acquired on the LSR II cytometer running FACSDiva 6 (BD 
Immunocytometry). Data were analyzed with FlowJo 7.6 (Treestar Software). 
ELISA 
 
Quantitative sandwich ELISA for cell culture supernatants were determined 
by colorimetric ELISA kits according to manufacturers’recommended 




Quantitative Multiplex for tissue homogenates were determined by bead-






Normally distributed data were analyzed by two-tailed Student’s t-test (for 
data containing two groups) or one-way ANOVA followed by Tukey’s post-test 
(for data with multiple groups). EAM severity scores were analyzed by Mann-




















Figure 2.1 Mice treated with anti-IL-6-receptor antibodies are 
protected from EAM 
 
EAM was induced in WT BALB/c mice treated with istotype control IgG 
antibodies or anti-IL-6-receptor antibodies on days 0 and 7. Mice were 
sacrificed 21 days post-immunization. Myocarditis severity was assessed by 
cardiac histopathology and heart-infiltrating cells were analyzed by flow 
cytometry. 
(A-B) Myocarditis severity was assessed by cardiac histopathological scoring 
using H&E staining. Data points represent individual mice. Bars represent 
mean. Data are analyzed by Mann-Whitney U test. Data are representative 
of 3 independent experiments.  
(C) Absolute number of intracardiac vital CD45+ leukocytes in heart. Data 
points represent individual mice. Bars represent mean. Data are analyzed by 
student’s T-test. 
(D) Systemic IL-6 levels measured from serum at day 21-post immunization 
by ELISA. Data points represent individual mice. Bars represent mean. Data 
are analyzed by student’s T-test. 
(E) Phosphorylated STAT-3 levels measured from total heart homogenate at 
day 21-post immunization by ELISA. Data points represent individual mice. 




Figure 2.1 Mice treated with anti-IL-6-receptor antibodies are 















Figure 2.2. Systemic IL-6 levels increase following immunization 
with CFA 
EAM was induced in WT BALB/c mice and serum levels of IL-6 were profiled 
in response to immunization. 
(A) EAM was induced in WT BALB/c mice. Blood was drawn on days 0, 3, 10, 
15, and 21 in order to assess serum IL-6 levels by ELISA.  Data points 
represent individual mice. Bars represent mean. Data are analyzed by one-
way ANOVA followed by Tukey’s post-test. *, p<0.05. 
 
(B) Mice were immunized with either CFA alone, without peptide (mock) or 
CFA containing the myosin-derived peptide (myosin). Blood was drawn on 
day 3 in order to assess serum IL-6 levels by ELISA.  Data points represent 











Figure 2.3. Recombinant IL-6 treatment restores susceptibility to 
EAM in IFA immunized mice 
EAM was induced in WT BALB/c mice using varying immunizations.  Mice 
were immunized with IFA or CFA, alone or with recombinant IL6 treatment 
on the day indicated (x-axis). Mice were sacrificed 21 days post-
immunization. EAM was assessed by histopathology. 
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Figure 2.4. IL-6 is only required for the initial response to 
immunization in order to induce EAM 
EAM was induced in WT BALB/c mice or IL-6KO mice treated with or 
without recombinant IL-6. Mice were sacrificed 21 days post-immunization. 
EAM was assessed by histopathology. 
(A) Schedule of recombinant IL-6 treatment and EAM immunization. 
(B) Histopathological scoring of EAM in mice hearts scored using H&E 
staining. Data points represent individual mice. Bars represent mean. Data 
are analyzed by one-way ANOVA followed by Tukey’s post-test. *, p<0.05. 
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Figure 2.5. IL-6 leads to differential DC profiles in the draining 
lymph node following immunization 
EAM was induced in WT BALB/c mice treated with istotype control IgG2b 
antibodies or anti-IL-6-receptor antibodies on days -3 and 0. Mice were 
sacrificed 3 days post-immunization.  
(A-B) Response to immunization was assessed by interrogating immune cells 
in the draining lymph node of the immunization site by flow cytometry. Data 
points represent individual mice. Bars represent mean. Data are analyzed by 
student’s T-test. Data are representative of 3 independent experiments. 
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Figure 2.6. IL-6 induces DC migration to the draining lymph node 
through DC CCR7+ expression and LN CCL21 expression 
EAM was induced in WT BALB/c mice treated with istotype control IgG2b 
antibodies or anti-IL-6-receptor antibodies on days -3 and 0. Mice were 
sacrificed 3 days post-immunization.  
(A) Response to immunization was assessed by interrogating immune cells in 
the draining lymph node of the immunization site by flow cytometry. Data 
points represent individual mice. Bars represent mean. Data are analyzed by 
student’s T-test. Data are representative of 3 independent experiments. 
(B) Total lymph node homogenates were assessed for CCL21 levels by ELISA. 
Data points represent individual mice. Bars represent mean. Data are 
analyzed by student’s T-test. 
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Figure 2.7. Cytokine and chemokine production in the immunization 
site draining lymph node 3 days post immunization 
EAM was induced in WT BALB/c mice treated with istotype control IgG2b 
antibodies or anti-IL-6-receptor antibodies on days -3 and 0. Mice were 
sacrificed 3 days post-immunization.  
(A-D) Total lymph node homogenates were assessed for protein levels of 
analytes by micro-bead array. Data points represent individual mice. Bars 











Chapter III: Interleukin 6 signaling on cardiac 




















In Chapter 2 we demonstrated that IL-6 is required to induce EAM during 
the induction phase of disease.  Following disease induction the role of IL-6 is 
undefined.  It is known that in patients with heart failure increased 
circulating levels of IL-6 correlate with poor outcomes.  We thus hypothesized 
that following EAM, during the progression to DCM, increased IL-6 levels 
would lead to decreased heart function.  The aims of this research were to 
define the role of IL-6 in the pathogenesis of DCM and describe the 
mechanism of action of IL-6.  
3.2 Results 
Circulating IL-6 levels during EAM correlate with heart failure 
progression 
It is known that in humans, increased circulating levels of IL-6 correlate with 
heart failure [4].  It has recently been shown that high circulating IL-6 is an 
independent risk factor for heart disease [92-94]. To investigate the 
correlation between circulating IL-6 during EAM to heart failure in DCM we 
interrogated levels of IL-6 in sera of mice with EAM.  WT BALB/c mice were 
immunized with MyHCα614-629 peptide emulsified in CFA at day 0 and 7 
and blood was drawn on day 21 of EAM (Figure 3.1).  Elevated serum IL-6 
levels at the peak of EAM at day 21, correlate with negative heart outcomes 
by echocardiography on day 45 (Figure 3.1). This mouse data corresponds to 
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the profile seen in human patients, validating the use of this model to 
interrogate the role of IL-6 in DCM development.  
IL-6 is required for the development of dilated cardiomyopathy 
In order to test whether IL-6 was necessary for DCM development, we 
treated mice with anti-IL-6R antibodies and followed these mice through to 
heart failure.  We have shown that this antibody blocks the development of 
EAM when given at the time of immunization (Figure 2.1).  Therefore to 
study the progression to DCM, we treated the mice with anti-IL-6R after the 
induction of EAM was already established (Figure 3.2). WT BALB/c mice 
were immunized with MyHCα614-629 peptide emulsified in CFA at day 0 
and 7 and separated into 3 different groups.  Mice were treated IV on days 
14, with 1mg and 21, with 0.5mg with either PBS alone, control isotype 
IgG2b antibodies or anti-IL-6R antibodies. Heart function was then evaluated 
by echocardiography on day 50 and following, the mice were euthanized for 
necropsy. Mice treated with anti-IL-6R antibodies retained normal heart 
function and were protected from ventricular dilation as compared with PBS 
or isotype treated mice (Figure 3.2). Thus, we established that the IL-6R 
signaling pathway is required for the development of DCM. 
Increasing circulating levels of IL-6 in BALB/c mice worsens heart 
function without altering fibrosis in the heart 
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In order to test whether increasing IL-6 levels in IL-6-competent mice could 
drive worsened heart failure, we increased the circulating levels of IL-6 in 
WT BALB/c mice during DCM.  To do this we employed hydrodynamic gene 
delivery of a plasmid containing an IL-6 insert under the control of a 
ubiquitous promoter.  Following IV injection of the plasmid containing the IL-
6 insert, circulating levels of IL-6 were elevated in the serum for up to 3 
weeks (Figure 3.3). Thus, this method provides an efficient tool for increasing 
the circulating levels of IL-6 in the mouse.  WT BALB/c mice were immunized 
with MyHCα614-629 peptide emulsified in CFA at day 0 and 7 and separated 
into 2 different groups.  Mice were injected IV on day 14 with 2 mL of saline 
containing 50 ug of plasmid either with no insert or the IL-6 insert. Heart 
function was then evaluated by echocardiography on day 45 and following, 
the mice were euthanized for necropsy. Mice treated with the plasmid 
containing the IL-6 insert developed worse heart function as compared with 
mice treated with the plasmid without the insert.(Figure 3.4A-B). It is 
important to note that both groups developed DCM, however the IL-6 
plasmid group had increased severity of DCM (Figure 3.4A-B). Thus, we 
established that further increases in IL-6 can drive worse heart function in 
DCM.  However, despite differing levels of heart function, both groups 
demonstrated similar levels of fibrosis in the heart (Figure 3.4C). These 
results were confirmed by analyzing fibrosis in earlier time points when 
effectors of fibrosis are normally altered in the model (Figure 3.5). This is 
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particularly interesting because it suggests that the effects of IL-6 in the 
heart are particularly important on the cardiac myocyte rather than cells 
responsible for cardiac fibrosis, which includes fibroblasts.  
In order to confirm that the IL-6 plasmid treatment was directly affecting 
heart function, the plasmid treatment of mice was also interrogated at day 21 
following day 14 IV hydrodynamic gene delivery. IL-6 plasmid treatment did 
not significantly alter the number of CD45+ cells infiltrating the heart 
(Figure 3.6), raising the possibility that the DCM phenotype was a result of 
IL-6 signaling on the cardiac resident cells, and not through changes to 
immune populations.  
IL-6 signaling through the cardiomyocyte is required for progression 
to dilated cardiomyopathy  
IL-6 worsens cardiac function without affecting the fibrosis in the heart 
(Figure 3.4- 3.6).  Blocking IL-6 signaling in the heart also protects the heart 
from heart failure (Figure 3.2). These two results taken together suggest that 
IL-6 may assert its pathogenic effects by acting on the cardiac myocyte. In 
order to test this hypothesis we studied the course of DCM in mice that do 
not have the ability to signal through IL-6 on the cardiac myocyte alone. IL-6 
signaling on the cardiac myocyte is through trans-signaling as the myocyte 
does not express the surface bound IL-6R required for classical signaling 
[107]. We obtained mice from the laboratory of Kirk Knowlton, GP CKO mice, 
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that lack myocyte IL-6 signaling by knocking out the gp130 receptor on the 
myocyte [158].  GP CKO mice have a myocyte-restricted knockout of the 
gp130 gene by employing a Cre-lox strategy.  The gp130 floxed allele mice 
contain 2 loxP sites in the transmembrane domain of gp130. The Cre mice 
delivered restriction to the myocyte using a knock-in strategy, utilizing Cre 
coding sequences into the genomic locus of the myosin light chain 2v (MLC2v) 
gene. Thus, GP CKO mice have normal IL-6 responses in every cell and 
tissue, including fibroblasts, except for the cardiac myocyte [158, 172, 173]. 
These mice provide a powerful tool to test the role of IL-6 in heart failure 
during EAM progression to DCM.  Naïve GP CKO have normal heart 
function (Figure 3.7) and are susceptible to EAM (Figure 3.8).  Additionally, 
during EAM, BALB/c and GP CKO mice have similar number of heart 
infiltrating CD45+ and CD4+ T cells (Figure 3.9). We have not observed any 
differences in proportion of IFNΥ+CD4+, IL17A+CD4+, and GM-CSF+CD4+ 
T cells in the hearts of GP CKO mice compared with WT animals during 
EAM (Figure 3.9). However, interestingly, GP CKO mice are completely 
protected from DCM (Figure 3.10A-C). WT BALB/c mice or GP CKO were 
immunized with MyHCα614-629 peptide emulsified in CFA at day 0 and 7. 
Heart function was assessed by echocardiography on day 45 and showed GP 
CKO mice were protected from heart failure and dilation (Figure 3.10B-C). 
Histopathology of mouse hearts showed that GP CKO were also protected 
from cardiac fibrosis, whereas WT BALB/c controls showed profound fibrosis 
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(Figure 3.10A).  Heart fibrosis was assessed for collagen deposition in the 
heart by Masson’s trichrome staining.  
In order to confirm that CFA immunization alone in GP CKO mice did not 
contribute to heart failure, GP CKO mice were ‘mock’ immunized, according 
to the same schedule and experiment, with CFA alone (without peptide).  
These mice did not develop EAM (Figure 3.8) or DCM (Figure 3.10A-C). 
Therefore, using GP CKO mice, we have shown that IL-6 signaling is 
required on the cardiac myocyte for the development of DCM (Figure 3.10A-
C).  
IL-6 induces IL-15 production by cardiomyocytes 
Having established that IL-6 signaling to cardiac myocytes is essential in 
driving cardiac failure during DCM, we sought to identify mechanism by 
which IL-6 exerts its effects. We isolated primary cardiac myocytes from 
adult WT mice and adult GP CKO mice and stimulated them with IL-6 alone 
(classical signaling), IL-6 and soluble-IL-6R together (trans-signaling) or IL-
1b (a known myocyte-responsive cytokine). After 24 hours the supernatant 
and the cardiac myocytes were collected. Supernatants were analyzed using a 
bead-based Multiplex array for protein concentration (Milltenyi).  Most of the 
cytokine and chemokines examined were comparable between conditions 
(Figure 3.11). However, WT myocytes produced IL-15 in response to IL-
6+soluble-IL-6R as opposed to stimulated GP CKO myocytes (Figure 3.12B-
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3.13A). This response was not seen with IL-6 alone, demonstrating myocytes 
require signaling in trans (Figure 3.12). This result was confirmed in heart 
homogenates from WT and GP CKO mice, comparing naïve to immunized 
mice sacrifice at day 21 of EAM (Figure 3.13B). It is known that IL-15 is 
made by myocytes in skeletal as well as cardiac tissue and is an autocrine 
cytokine that protects cells from apoptosis. Therefore, this result uncovers a 
fascinating role of IL-6 in the basic biology of myocyte signaling, and suggests 
IL-15 autocrine signaling may contribute to chronic IL-6-mediated alteration 
of myocyte function.  
IL-6 signaling to the cardiomyocyte alters the profile of heart-
function-related proteins associated with depressed myocyte 
contraction and heart dilation 
Chronic IL-6 signaling reduces the basal contractility of the myocyte, induces 
a hypertrophic response and ultimately results in loss of myocyte function 
[156, 172, 173].  Therefore, we investigated whether the mechanism of IL-6 in 
the pathogenesis of EAM-associated DCM was depressing the contractile 
capability of the myocyte.  IL-6 was shown to down-regulate proteins 
required for the pumping of calcium, called SERCA (sarcoendoplasmic 
reticulum calcium transport ATPase) proteins, in myocytes in vitro [174].  
Additionally, in vitro, IL-6 up regulates atrial natriuretic peptide (ANP) and 
brain natriuretic peptide (BNP), which mediate loss of myocyte function 
[175].  Therefore, we examined the levels of these proteins from the hearts of 
 56 
WT BALB/c mice compared with GP CKO mice during DCM by Western Blot 
(Figure 3.14A-C).   
SERCA proteins are calcium-ATPases that reside in the sarcoplasmic 
reticulum (SR) of the myocyte that  transfer calcium from the cytosol to the 
SR for muscular excitation and contraction [176]. SERCA2 is the isoform 
found in the cardiac myocyte specifically [177, 178]. Decreased SERCA2 
expression correlates to depressed myocyte contraction [179].  Hearts from 
WT BALB/c mice during DCM have lower levels of SERCA2 than GP CKO 
mice (Figure 3.14A).  This suggests that IL-6 signaling during DCM 
depresses cardiac myocyte function as GP CKO mice, which are protected 
from DCM, do not display this phenotype (Figure 3.10).  
Additionally, WT BALB/c mice have higher levels of ANP and BNP proteins 
(Figure 3.14B-C). ANP, atrial natriuretic peptide, is released from myocytes 
in response to mechanical stress [180]. BNP, brain natriuretic peptide, is 
released primarily from the heart [181].  The release of ANP and BNP is 
increased in patients with heart failure [182]. ANP and BNP levels increase 
in response to changes in heart filing pressures [183]. The increase seen in 
ANP and BNP levels in the hearts of WT BALB/c mice compared with GP 
CKO mice is further evidence that IL-6 signaling on the cardiac myocyte is 
driving DCM through the loss of myocyte function (Figure 3.14A-C).  
Therefore, during EAM, IL-6 signals to the cardiac myocyte causing loss of 
function and driving heart failure in DCM.  
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3.3 Conclusions 
In patients with heart failure, increases in circulating levels of IL-6 correlate 
with negative heart outcomes [105].  This association has been extensively 
studied and it was recently shown that high levels of circulating IL-6 are an 
independent risk factor for heart disease in healthy people [91].  Patients 
with DCM have been shown to have multiple changes in IL-6 signaling [154].  
DCM patients have higher levels of IL-6 in the circulation [162, 163] but have 
also been shown experimentally to have changes associated with IL-6R 
signaling as well [154].  For these reasons we examined the role of IL-6 in 
EAM-associated DCM.  Similar to patients, we demonstrated that higher 
concentrations of IL-6 in the serum of mice during EAM predict poor heart 
outcomes during the DCM phase of disease. This result led us to investigate 
the mechanism by which IL-6 exerts its pathogenic effects. 
We have shown that IL-6 is required for the development of EAM. However, 
once EAM has been established, IL-6 levels remained chronically elevated 
compared to baseline IL-6 concentrations in the serum. Therefore we 
examined what role this proinflammatory cytokine was playing in the 
development of heart failure.  Using an anti-IL-6R antibody treatment during 
EAM, we demonstrated that IL-6 is required for the development of DCM.  
Mice treated with an anti-IL-6R antibody at days 14 and 21 of EAM were 
completely protected from DCM, with normal both heart function by 
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echocardiography and no development of fibrosis by hydroxyproline as 
compared with PBS or isotype treated mice. 
Knowing that high levels of circulating IL-6 are associated with heart failure, 
we investigated whether we could drive disease progression further by 
increasing IL-6 levels.  Using IL-6-competent BALB/c mice, we utilized 
hydrodynamic gene delivery to in order to artificially increase circulating IL-
6.  Mice that had increased IL-6 levels above the normal course of IL-6 
induction during disease had hearts which were more dilated and had worse 
heart function compared with untreated mice.  However, the loss of heart 
function was not accompanied by worsened fibrosis in the heart. Both treated 
and untreated mice developed fibrosis, but treated mice, with worse heart 
function, did not have increased fibrosis above the normal course of disease.  
We further confirmed these results by interrogating mediators of fibrosis 
earlier in disease. We demonstrated that various mediators of fibrosis, 
including matrix metalloproteinases (MMPs), tissue inhibitors of matrix 
metalloproteinases (TIMPs) and collagen levels were unchanged between 
groups during EAM.  In order to directly relate the heart dilation phenotype 
to myocytes we interrogated the heart infiltrating immune populations of 
treated and untreated mice during EAM showing that infiltrating 
populations were not significantly altered during hydrodynamic gene 
delivery.  Thus, we determined that the decreased heart function associated 
with increased IL-6 levels was due to direct effects on the heart. This was 
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particularly interesting as the evidence suggested that the pathogenic effects 
of IL-6 were specifically attributed to function alone and not fibrosis.  
In order to address the IL-6 differences in function versus fibrosis we 
examined the cell types of the heart responsible for each.  IL-6 signaling on 
cardiac fibroblasts is known to produce mediators of fibrosis whereas heart 
function is attributed to cardiac myocytes.  Thus, we investigated the role of 
IL-6 signaling on cardiac myocytes. In order to isolate the signaling on 
myocytes, we employed genetically altered mice.  GP CKO mice have a cre-lox 
knock-in deletion of the gp130 cellular receptor on myocytes alone [158].  
These mice have myocytes that cannot respond to IL-6 because the cells lack 
the signaling receptor gp130 required [158]. GP CKO mice are 
developmentally normal, with normal heart function during homeostasis 
[158, 172, 173].  GP CKO mice have heart function comparable with WT 
BALB/c mice (Supplemental Figure 5).  Thus, GP CKO mice are a powerful 
tool in which to study the IL-6 effects on the myocyte.   
Using GP CKO mice, we demonstrated that IL-6 signaling on the cardiac 
myocyte is required for the development of DCM.  We demonstrated that GP 
CKO develop WT BALB/c-comparable EAM, but are completely protected 
from the progression to DCM.  Thus, IL-6 signaling on the cardiac myocyte is 
required for the development of DCM. 
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In order to determine the mechanism by which IL-6 signaling to the cardiac 
myocyte causes DCM we interrogated the cardiac cells in vitro and the hearts 
in vivo, between genotypes. We isolated cardiac myocytes from naïve WT 
BALB/c and GP CKO hearts and treated them in vitro with cytokines.  
Myocytes make few cytokines and chemokines.  Many of the targets we 
interrogated were found to be unchanged, however, interestingly we showed 
that myocytes make IL-15 in response to IL-6+solubleIL-6R signaling.  IL-15 
is an autocrine hormone known to be anti-apoptotic to skeletal muscle [184] 
which is interesting because IL-6 is known to be anti-apoptotic to cardiac 
myocytes [185].  
IL-15 is known to be produced by muscle cells, in the heart and periphery 
[186].  In the immune system, IL-15 acts similarly to IL-2, however IL-15 
preferentially stimulates CD8+ T cells rather than CD4+ T cells [187].  It is 
known that EAM is driven by CD4+ T cells, rather than CD8+ T cells, 
therefore additional IL15 biology was investigated.  
Interestingly, IL-15 is known to be an anabolic cytokine in skeletal muscle 
that protects the cells from apoptosis [184].  IL-6 is known to be anti-
apoptotic to the cardiac myocyte [158], suggesting that one of the 
mechanisms by which IL-6 preserves myocytes from death might be through 
IL-15 upregulation. Chronic IL-6 signaling on the myocyte is anti-apoptotic, 
but eventually leads to myocytes with ineffective pumping capacity. These 
results demonstrated that one of the ways IL-6 may exert anti-apoptotic 
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effects in the cardiac myocyte may be through IL15 expression.  These 
experiments demonstrated interesting IL-6 basic biology, but did not reveal 
the specific mechanism of IL-6 pathogenesis on the myocyte. 
Chronic IL-6 signaling has been shown to decrease basal contractility of the 
myocyte, induce a hypertrophic genetic profile in the myocyte and lead to loss 
of pumping function [145, 153].  Because we have demonstrated that IL-6 
acts through the myocyte to drive DCM, we then examined whether the 
pathogenic effects of IL-6 in DCM were due to direct depression of myocyte 
function.  
To study the function of the cardiac myocyte in vivo during DCM we 
examined the production of myocyte-derived contractile proteins.  We 
interrogated the levels of 3 proteins, known to be made in the myocyte, which 
are direct correlates to myocyte function. We studied the protein expression, 
by Western blot, of sarcoendoplasmic reticulum calcium transport ATPase-2 
(SERCA2), atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP) during DCM.  SERCA2 is the heart isoform within SERCA proteins 
and is required for myocyte excitation and contraction [176, 188]. SERCA 
expression is decreased in heart failure [189]. Additionally, SERCA gene 
transfer has been experimentally shown to restore contractile function in 
myocytes isolated from failing hearts [190]. During the DCM phase after 
immunization, WT BALB/c mice have lower levels of SERCA2 when 
compared to immunized GP CKO mice, which are protected from heart 
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failure. This suggests that IL-6 signaling on the myocyte causes dilation in 
part due to decreased SERCA2 protein expression, which is known to depress 
cardiac function [175, 176].  
ANP and BNP are two additional proteins made by myocytes [183].  Both 
have been shown to be increased in failing hearts [181].  ANP and BNP are 
released by the myocyte in response to mechanical stress [181].  They are 
produced by failing hearts as a protective measure but are a signal of loss of 
function [183]. WT BALB/c mice have higher levels of both ANP and BNP in 
their hearts during DCM compared with GP CKO mice, which are protected 
from DCM.  These results provide additional evidence to the result that IL-6 
causes loss of function of the myocyte, as demonstrated by loss of SERCA2 
expression. Taken together, the profile of expression of these 3 proteins 
suggest that the mechanism by which IL-6 signaling on the myocyte leads to 
DCM is through the direct loss of myocyte function.   
Thus, we have shown that IL-6 is required for DCM.  Specifically, IL-6 
signaling on the cardiac myocyte is required for DCM. Mechanistically, IL-6 
signaling on the myocyte results in decreased SERCA expression and 
increased ANP and BNP expression, together signifying myocyte loss of 
function.  In addition, we have shown that one of the ways in which IL-6 
exerts an anti-apoptotic effect on the cardiac myocyte may be through IL15 
expression and subsequent autocrine signaling.  Therefore IL-6 drives 
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progression of EAM to DCM by altering proteins associated with decreased 
myocyte function. 
It is known that IL-6 contributes not only to DCM, but to many heart 
diseases [91, 92].  Our investigation has delineated IL-6 biology on the 
myocyte that is applicable to many of these diseases.  As in many heart 
diseases, circulating IL-6 levels increase during EAM, and we have 
investigated the mechanism by which IL-6 drives subsequent heart failure. 
These results demonstrate that IL-6 signaling on the myocyte drives heart 
failure, which is particularly interesting for human health because of the 
mechanics of IL-6 signaling to the myocyte.  Because myocytes require IL-6 to 
signal in trans, due to their lack of the membrane-associated IL-6R necessary 
for classical signaling, therapeutic targeting of the soluble IL-6R presents the 
opportunity to affect pathogenic signaling while preserving the other classical 
signaling functions of IL-6 required systemically. This would be particularly 
important for heart failure patients requiring long term therapeutics, where 
classical IL-6 signaling would be required for normal response to insult or 





3.4 Materials and Methods 
Mice 
WT BALB/cJ and IL-6-/- BALB/c mice were purchased from the Jackson 
Laboratory. GP CKO mice were a generous gift from the laboratory of Kirk 
Knowlton at the University of California, San Diego. All mice were 
maintained in the Johns Hopkins University School of Medicine specific-
pathogen free vivarium. Experiments were conducted on 6-8 week old male 
mice, in compliance with the Animal Welfare Act and the principles set forth 
in the Guide for the Care and Use of Laboratory Animals. All methods and 
protocols performed were approved by the Animal Care and Use Committee 
of The Johns Hopkins University. 
Induction of EAM and DCM 
To induce EAM, we employed the myocarditogenic peptide of cardiac myosin 
heavy chain, MyHCα614-629 (Ac-SLKLMATLFSTYASAD). The peptide was 
commercially synthesized by fMOC chemistry and purified to a minimum of 
90% by HPLC (Genscript). On days 0 and 7, mice received an axillary 
subcutaneous immunization of 100 μg of MyHCα614-629 peptide emulsified 
in either complete Freund’s adjuvant (CFA) (Sigma) supplemented to 5 
mg/mL of heat-killed Mycobacterium tuberculosis strain H37Ra (Difco) or 
incomplete Freund’s adjuvant (IFA) (Sigma). On day 0, mice additionally 
received 500 ng of pertussis toxin intraperitoneally. (List Biologicals).  
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Assessment of EAM Histopathology 
Mouse hearts were evaluated for the development of EAM on day 21 or DCM 
around day 45. Heart tissues were fixed in SafeFix solution (Fisher 
Scientific). Tissues were embedded in paraffin block longitudinally, and 5 μm 
serial sections were cut. Staining for EAM at day 21 was with hematoxylin 
and eosin (H&E), staining for DCM around day 45 was with Masson’s 
trichrome blue (HistoServ, Gaithersburg, MD). Myocarditis severity was 
evaluated by visually determining the area of the myocardium infiltrated 
with hematopoietic cells.  The area was infiltrated was evaluated using the 
published scoring system: grade 0, no inflammation; grade 1, less than 10% of 
the heart section is involved; grade 2, 10-25%; grade 3, 25-50%; grade 4, 50-
75%; grade 5, more than 75%. Grading was performed by evaluating 3 
sections per heart by two independent, blinded investigators. Values from the 
3 section grading and both evaluators were averaged. The same methods 
were utilized in order to score the area of the heart covered by interstitial 
fibrosis after staining of sections with Mason’s Tricome. 
Flow Cytometry Analysis and FACS Isolation of Heart Infiltrating 
Cells 
To prepare the cellular infiltrating populations for flow cytometry analysis, 
single cell suspensions were made from mouse hearts.  Hearts were perfused 
for 3 min with 1x phosphate buffered saline (PBS) + 0.5% FBS, and digested 
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in GentleMACS C Tubes according to manufacturer’s instructions (Miltenyi 
Biotec). Viability was determined by LIVE/DEAD staining according to 
manufacturer’s instructions (Life Techonologies). Cells were blocked with 
αCD16/32 (eBiosciences), and surface markers were stained with 
fluorochrome-conjugated mAbs (eBioscience, BD Pharmingen, BioLegend). 
Samples were acquired on the LSR II cytometer running FACSDiva 6 (BD 
Immunocytometry). Data were analyzed with FlowJo 7.6 (Treestar Software). 
Echocardiography 
Trans-thoracic echocardiography was performed using the Acuson Sequoia 
C256 ultrasonic imaging system (Siemens). Prior to evaluation, the chest of 
the mouse was  shaved using depilatory cream (Nair). Conscious mice were 
held in supine position. The heart was imaged in two-dimensional (2-D) mode 
in the parasternal short axis view. From this mode, an M-mode cursor was 
positioned perpendicular to the interventricular septum (IVS) and the left 
ventricular posterior wall (LVPW) at the level of the papillary muscles. From 
M-mode, the wall thicknesses and chamber dimensions were measured. For 
each mouse, three to five values for each measurement were obtained and 
averaged for evaluation. The left ventricular end-diastolic dimension 
(LVEdD), LV end-systolic dimension (LVEsD), interventricular septal wall 
thickness at end-diastole (IVSD), and LV posterior wall thickness at end 
diastole (LVPWTED) were measured from a frozen M-mode tracing. 
Fractional shortening (FS), ejection fraction (EF) and relative wall thickness 
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(RWT) were calculated from these parameters as previously described 
(Baldeviano et al., 2010). 
In vivo hydrodynamic gene delivery 
Mammalian expression vectors (pORF plasmids) encoding the intronless 
murine cDNA for IL-6 (pORF-mlL-6) were obtained from Invivogen (San 
Diego, CA). Plasmids were transformed into competent GT100 E. coli 
bacteria and grown on 250 mL of LB broth containing ampicillin (100 ug/mL). 
Large-scale preparation of plasmids was performed using the endotoxin-free 
Maxiprep kit from Qiagen (Valencia, CA). Following quantification by a 
nanodrop spectrophotometer, 25 ng of plasmid was dissolved in 2 mL of 
Ringer's lactate solution, and injected into mice by the tail vein. In vivo 
expression was confirmed by ELISA quantification of IL-6 from sera of mice. 
Mice injected with pORF-mlL-6 or empty pORF plasmid were immunized 
with MyHC6i4-629/CFA the next day to induce EAM. 
Gel Zymography 
MMPs were measured by gel zymography using previously published protocol 
[191]. Briefly, heart tissue was homogenized in lysis buffer (25 mM Tris-HCI, 
pH 7.5; 100 mM NaCI; and 1% v/v Nonidet P-40), and cell debris was 
removed by centrifugation. Total protein was quantified by BCA protein 
assay kit (Thermo scientific, Rockford, IL). Twenty-five micrograms of total 
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protein was loaded into a precast 10% Tris-Glycine gel with 0.1% gelatin 
(Invitrogen). Gels were developed and stained as reported elsewhere [191]. 
Real-Time Quantitative PCR 
 
Tissue total RNA was extracted in TRIZOL (Life Technologies). cDNA were 
synthesized with High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) and amplified with Power SYBR Green Mastermix (Life 
Technologies) in MyiQ2 thermocycler (Bio-Rad) running iQ5 software (Bio-
Rad). Data were analyzed by the 2–ΔΔCt method of Livak, et al., comparing 
threshold cycles first to Hprt expression, then ΔCt of target genes in 
controls[192]. 
Hydroxyproline Assay 
Heart samples were weighed, homogenized in de-ionized water, and then 
hydrolyzed in 6N HCl overnight at 120℃. Lysates are transferred and 
desiccated in 96-well plates, and reconstituted in de-ionized water. After 
incubation with 50 mM Chloramine T (Sigma), followed by 1M 
dimethylaminobenzaldehyde (Sigma), the OD values are read at 570 nm. The 
concentration of hydroxyproline is determined by a 1-100 μg/mL standard 
curve of hydroxyproline (Sigma) and normalized to starting heart sample 
mass [193]. 
Isolation of Primary Adult Mouse Cardiac Myocytes 
 69 
Hearts were dissected from 6-8 week old male mice pre-treated with heparin, 
aorta were cannulated, and hearts were perfused with calcium-free perfusion 
buffer, and digested by type II collagenase (Worthington). Cardiomyocytes 
were separated from resulting suspensions by their rapid spontaneous 
precipitation. Isolated cardiomyocytes were cultured in mouse laminin-coated 
plates or chamber slides and used for experiments after 24 hours.  
ELISA 
 
Quantitative sandwich ELISA for cell culture supernatants weredetermined 
by colorimetric ELISA kits according to manufacturers’recommended 
protocols (R&D Systems and Sigma). 
Multiplex  
Quantitative Multiplex for tissue homogenates were determined by bead-
based Multiplex kits according to manufacturers’ recommended protocols 
(Milltenyi). 
Western Blot 
Tissues or cells were collected in RIPA buffer with anti-protease enzymes 
(Sigma). Total protein was quantified by BCA assay (Thermo Scientific). 20μg 
of sample was separated on a 10% SDS-PAGE Mini-Protean precast gels (Life 
Technologies). Bands were transferred to PVDF membrane (vendor). 
SERCA2 was blotted with mAb clone 2861 (Cell Signaling), BNP was blotted 
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with mAb clone 19645 (Cell Signaling), ANP was blotted with mAb clone 
14348 (Cell Signaling), and β-actin was blotted with mAb clone 13E5 (Cell 
Signaling). HRP-conjugated secondary antibodies (Jackson ImmunoResearch) 
and Amersham ECL Prime detection system (GE Healthcare) were used to 
visualize the bands.  
Statistics 
Normally distributed data were analyzed by two-tailed Student’s t-test (for 
data containing two groups) or one-way ANOVA followed by Tukey’s post-test 
(for data with multiple groups). EAM severity scores were analyzed by Mann-
Whitney U test (up to two groups) or Kruskal-Wallis test followed by Dunn’s 













3.5 Figures and tables 
 
Figure 3.1. Circulating IL-6 levels during EAM correlate with heart 
failure progression 
EAM was induced in WT BALB/c mice and serum levels of IL-6 were profiled 
at day 21 and then compared to the echocardiography functional outcome at 
day 45. EAM was induced in WT BALB/c mice. Blood was drawn on day 21 in 
order to assess serum IL-6 levels by ELISA.  The heart function of the mice 
was assessed at day 45.  The levels of IL-6 at day 21 were correlated with the 
corresponding mouse’s echocardiography parameters at day 45 [Fractional 
shortening (above) as well as ejection fraction (not shown)]. Data points 
represent individual mice. Data are analyzed by linear regression and 
correlation analysis.  
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Figure 3.2. IL-6 is required for the development of dilated 
cardiomyopathy 
EAM was induced in WT BALB/c mice treated with PBS, istotype control 
IgG2b antibodies or anti-IL-6-receptor antibodies on days 14 and 21. DCM 
was assessed by echocardiography for heart function by measuring ejection 
fraction (EF) of the heart. Mice were sacrificed 45 days post-immunization. 
Data points represent individual mice. Bars represent mean and standard 
deviation. Data are analyzed by one-way ANOVA followed by Tukey’s post-






Figure 3.3. Serum levels of IL-6 following hydrodynamic gene 
delivery of plasmid containing IL-6 insert 
Naïve mice were injecting with a plasmid containing an IL-6 insert. Blood 
was drawn on days 0, 7, 14, and 21 in order to assess serum IL-6 levels by 











Figure 3.4. Increasing circulating levels of IL-6 in wild-type BALB/c 
mice worsens heart function without altering fibrosis in the heart 
 
EAM was induced in WT BALB/c mice with HGD of a plasmid with no insert 
‘pORF-blank’ or an IL-6 containing insert ‘pORF-IL6’ on day 7. Mice were 
sacrificed 45 days post-immunization. DCM was assessed by 
echocardiography and collagen deposition in the heart. Data are 
representative of 3 independent experiments.  
(A-B) Echocardiography of mice at day 45.  Ejection fraction and left ventricle 
end diastolic diameters (LVEDD) were measured on awake mice. Data points 
represent individual mice. Bars represent mean. Data are analyzed by 
student’s T-test. 
(C) Collagen deposition was assessed by the measurement of hydroxyproline 
levels in the hearts. Data points represent individual mice. Bars represent 
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mice worsens heart function without altering fibrosis in the heart
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Figure 3.5 Hydrodynamic gene delivery does not alter fibrosis during 
EAM 
EAM was induced in WT BALB/c mice with HGD of a plasmid with no insert 
‘pORF-blank’ or an IL-6 containing insert ‘pORF-IL6’ on day 7. Mice were 
sacrificed 14 or 21 days post-immunization. Fibrosis was assessed. 
(A) Mice were sacrificed at day 14 and fibrosis was assessed by gel 
zymography for MMP2 and MMP9 levels.  Data points represent individual 
mice. Bars represent mean. Data are analyzed by student’s T-test. 
(B) Mice were sacrificed at day 21 and fibrosis was assessed by qPCR for 
mRNA levels of fibrosis associated targets. Data points represent individual 












Figure 3.6 Hydrodynamic gene delivery does not alter heart-
infiltration populations during EAM 
EAM was induced in WT BALB/c mice with HGD of a plasmid with no insert 
‘pORF-blank’ or an IL-6 containing insert ‘pORF-IL6’ on day 7. Mice were 
sacrificed 21 days post-immunization. EAM was assessed by histopathology 
and flow cytometry. 
(A) Histopathological determination of EAM. Heart sections were stained 
with H&E and cellular infiltration into the heart was assessed. (NS) 
(B) Total intracardiac CD45+ leukocytes in mice hearts. Data points 
represent individual mice. Bars represent mean. Data are analyzed by 





Figure 3.7 GP CKO mice have normal heart function over time 
Naïve GP CKO mice were assessed for heart function, serially, over 36 weeks 
by echocardiography for ejection fraction (EF).  
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Figure 3.8 EAM develops in GP CKO mice 
EAM was induced in WT BALB/c mice, GP CKO mice or mock-immunized GP 
CKO mice. Mice were sacrificed 21 days post-immunization. EAM was 
assessed by histopathology. Histopathological scoring of EAM in mice hearts 
scored using H&E staining. Data points represent individual mice. Bars 
represent mean. Data are analyzed by one-way ANOVA followed by Tukey’s 






Figure 3.9 BALB/c and GP CKO mice develop similar heart-
infiltrating populations during EAM 
EAM was induced in WT BALB/c mice or GP CKO mice. Mice were sacrificed 
21 days post-immunization. EAM was assessed by heart-infiltrating cells and 
T-cell subsets and analyzed by flow cytometry. 
(A) Total intracardiac CD45+ leukocytes in mice hearts. Data points 
represent individual mice. Bars represent mean. Data are analyzed by 
student’s T-test. Data are representative of 3 independent experiments.  
(B) Total intracardiac CD4+ cells in mice hearts expressed as a percentage of 
total CD45+ cells. Data points represent individual mice. Bars represent 
mean. Data are analyzed by student’s T-test. Data are representative of 3 
independent experiments.  
(C-E) Intracellular cytokine staining of total intracardiac CD4+ cells in mice 
hearts. Data points represent individual mice. Bars represent mean. Data are 
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Figure 3.10. IL-6 signaling to the cardiomyocyte is required for 
progression to DCM  
EAM was induced in WT BALB/c mice, GP CKO mice or mock-immunized GP 
CKO mice. Mice were sacrificed 45 days post-immunization. DCM was 
assessed by histopathology and echocardiography.  
(A) Histopathological scoring of DCM in mice hearts scored using Masson’s 
trichrome blue staining. Data points represent individual mice. Bars 
represent mean. Data are analyzed by one-way ANOVA followed by Tukey’s 
post-test. *, p<0.05. Data are representative of 3 independent experiments.  
(B-C) Echocardiography to assess heart function of ejection fraction (EF) and 
left ventricle end systolic diameter (LVESd). Data points represent individual 
mice. Bars represent mean. Data are analyzed by one-way ANOVA followed 
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Figure 3.11 GP-CKO Myocytes have decreased production of CCL3, 
CCL4 and IL-1a in response to IL-6 in vitro. 
Primary adult mouse cardiomyocytes from BALB/c or GP CKO naïve adult 
mice were cultured with rIL6+sIL6R for 24 hours. Supernatant was collected 
after culture, and the levels of chemokines and cytokines were measured by 
multiplex bead array. The red dotted lines represent the threshold level of 




Figure 3.12. Myocytes require IL-6 signaling in trans rather than 
classical signaling in vitro 
 
Primary adult mouse cardiomyocytes from BALB/c or GP CKO naïve adult 
mice were cultured for 24 hours. Supernatant were collected after culture, 
and the levels of chemokines and cytokines were measured by multiplex bead 
array. The red dotted lines represent the threshold level of detection of the 
assay.  
(A)  In order to test the viability and responsiveness of the myocytes, 
myocytes were treated with IL-1b as a positive control. 
(B)  In order to test whether the myocytes signaled through classical IL-6 
signaling (IL-6 alone) or trans signaling (sIL-6R+IL-6) myocytes were 
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Figure 3.13 IL-6 induces IL-15 production by the cardiomyocyte 
IL-15 induction in vitro and vivo by cardiac myocytes. 
(A) Primary adult mouse cardiomyocytes from BALB/c or GP CKO naïve 
adult mice were cultured with rIL6+sIL6R for 24 hours. Supernatant were 
collected after culture, and the levels of IL-15 were measured by multiplex 
bead array. The red dotted lines represent the threshold level of detection of 
the assay.  
(B) Mouse heart homogenates from naïve or EAM induced mice at day 21. 
EAM was induced in WT BALB/c mice or GP CKO mice. Mice were sacrificed 
21 days post-immunization or age-matched for naïve mice. IL-15 levels were 







Figure 3.14 IL-6 signaling on the cardiomyocyte alters the profile of 
heart-function-related proteins 
EAM was induced in WT BALB/c mice or GP CKO mice. Mice were sacrificed 
45 days post-immunization. Whole heart homogenate was prepared for 
Western blot analysis. These blots are representative of 3 independent 
experiments.  
(A) Western blot immunostained for sarcoendoplasmic reticulum calcium 
transport ATPase (SERCA-2). BALB/c mice have less SERCA-2 than GP 
CKO mice. Secondary band in addition to 110 kDa band is a known 
background band (abcam).  
(B) Western blot immunostained for brain natriuretic peptide BNP. BALB/c 
mice have more BNP than GP CKO mice. 
(C) Western blot immunostained for atrial natriuretic peptide ANP. BALB/c 
mice have more ANP than GP CKO mice. 





































4.1 General Overview  
Myocarditis and the consequences of this inflammation on heart function is a 
leading cause of sudden death in young adults [18].  Unresolved myocarditis 
can progress to DCM, a chronic disease that may result in heart failure. 
Myocarditis and myocarditis-associated DCM account for 45% of all heart 
transplants required in the United States [28]. The mechanisms driving the 
progression from myocarditis to heart failure are largely unknown. 
Identifying biomarkers of disease progression or targets of therapeutic 
intervention are needed for patient management.  Currently, DCM is only 
cured by heart transplantation and management is restricted to general 
heart failure drugs for symptom treatment [27].  
Increased IL-6 levels are associated with heart failure and are found in 
patients with DCM [105].  IL-6 levels represent an independent risk factor for 
CVD [91].  Employing the mouse model of myocarditis, EAM, the results 
presented in this dissertation has demonstrated the mechanisms by which 
IL-6 induces myocarditis and drives its progression to dilated 
cardiomyopathy. Chronically elevated IL-6 levels are a surrogate marker of 




4.2 IL-6 in the priming phase of EAM 
In addition to the identification of the role IL-6 plays in the progression of 
myocarditis to heart failure, this dissertation has described the critical role of 
IL-6 in the induction of myocarditis.  In chapter 2 some of the basic steps by 
which IL-6 acts to promote the immune response to cardiac myosin-peptide 
are explored and shows for the first time that IL-6 enhances and broadens 
the response to adjuvant.  
IL-6KO mice are known to be resistant to EAM induction [128].  Using anti-
IL-6R antibodies we proved that IL-6 is required to induce EAM in mice that 
have developed in an IL-6 sufficient environment.  Previous research has 
shown that IL-6KO mice do not develop any immune cell infiltration 
following immunization, but have not explained why or when IL-6 is 
required.  
Using IL-6KO mice treated with recombinant IL-6, we isolated the role of IL-
6 in the initial priming phase of EAM.  IL-6KO mice treated with 
recombinant IL-6 cytokine for only 4 days surrounding the first 
immunization developed robust EAM not previously reported in IL-6KO mice. 
This determined the window in which IL-6 is needed for the pathogenic 
development of an autoimmune reaction to the heart. We conclude that IL-6 
shapes the initial immune response to cardiac myosin peptide that will later 
develop into an immune reaction against the myocardium.  
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4.2.1 IL-6 and the response to adjuvant 
Since IL-6 is required for the response to immunization, we sought to 
determine if IL-6 is a required factor for a response to adjuvant.  It is known 
that the adjuvants commonly used for mice immunizations, CFA and IFA, 
induce very different responses during EAM [171].  CFA immunization is 
used to induce EAM because IFA immunization does not induce any disease 
in the heart.  IFA immunization will induce antibody responses to 
immunization, as myosin-reactive antibodies can be measured following IFA 
immunization, but no EAM develops.  EAM is T-cell driven and antibodies 
alone cannot induce disease [12, 13].   
Supplementing IFA with rIL-6 at either first immunization on day 0 or at the 
boost on day 7, we show that the EAM development, and a robust and 
pathogenic immune response to the heart, is partially dependent upon IL-6.  
Mice immunized with IFA that received a single injection of recombinant IL-6 
at the time of immunization developed immune-cell infiltration into the 
heart. The level of this EAM development was not equivalent to CFA-induced 
EAM, implying that other factors in addition to IL-6 are induced by CFA and 
lead to severe EAM. 
4.2.2 IL-6 drives the local immune response through dendritic cells 
We established that IL-6 was required, in low doses, for the priming phase of 
EAM induction. We then sought to determine the mechanism why IL-6 was 
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required for EAM. Using WT-BALB/c mice treated with anti-IL-6R antibodies 
or isotype control antibodies, we examined the local lymph node response to 
IL-6 signaling during immunization.  We pre-treated mice with antibodies to 
create an environment either sufficient or void of IL-6R signaling and then 
immunized the mice with peptide-CFA.  Three days following immunization 
we interrogated the chemokines and cytokines produced, and the cellular 
response in the draining lymph node.  Through these experiments, we 
demonstrated that IL-6 is required to induce dendritic cell (DC) trafficking to 
the lymph node shown by DC CCR7 expression and lymph node CCL21 
expression.  This finding supports previous reports that IL-6 induced CCL21 
expression by lymph node endothelial cells is required for CCR7+ DC 
trafficking [194].  
In Chapter 2 we report that IL-6 is required for the initial response to 
immunization in order to induce DC responses in the local lymph node.  We 
further show that IL-6 is required for an immune response to adjuvant that 
induces T-cell, rather than solely B-cell, responses, leading to EAM. These 
experiments clarify the role of IL-6, not only in EAM, but also as applied to 
adjuvant uses, such as vaccine development.  Identifying that the induction of 
IL-6 in response to adjuvant changes a limited, B-cell response, into a 
pathogenic, T-cell involved response, can be incredibly informative for 
designing ideal immune responses to vaccines.  Alternatively, this knowledge 
could be used to try and intervene in a pathogenic response to self, by 
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targeting IL-6 induced pathogenic responses dependent on DC sub-
populations.  
4.3 IL-6 in progression of EAM to DCM 
After describing the role of IL-6 in disease induction we examined the role of 
IL-6 in the progression of myocarditis to DCM.   
Using anti-IL-6R antibodies in WT BALB/c mice, we discovered that IL-6 is 
required for the development of DCM, as mice receiving the anti-IL-6R 
antibodies were protected from DCM even after EAM had been established.  
Treatment by anti-IL-6R antibodies during effector stage of EAM was an 
important experiment in order to show the therapeutic potential of targeting 
IL-6 without having to intervene in the initial immune response to cardiac 
myosin.   
In order to confirm that IL-6 is critical in driving DCM, we approached the 
question by an opposite experiment.  If blocking IL-6 protected from DCM 
development, could increasing IL-6 production worsen DCM?  
Using hydrodynamic gene delivery of plasmid-IL-6 to mice with EAM, we 
showed that IL-6 drives functional parameters of heart failure while sparing 
further cardiac fibrosis.  Mice that expressed higher than WT levels of IL-6 
after EAM was established had diminished cardiac function, as characterized 
by a decreased ejection fraction, fractional shortening and more dilated 
hearts as measured by left ventricle end diastolic diameter and left ventricle 
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end systolic diameter.  Thus, elevated IL-6 levels systemically contributed to 
heart dilation and failure.  Both groups, regardless of plasmid insert, 
developed expected levels of fibrosis in the heart.  But, the group with the 
higher IL-6 levels did not develop worse fibrosis.  This novel finding suggests 
that the heart failure was not driven by enhanced fibrosis, but rather could 
depend upon the cell responsible for heart pumping function, the myocyte.  
 
4.3.1 IL-6 signaling in the heart drives DCM through its depressive 
effects on the cardiac myocyte  
In order to study the IL-6 contribution to DCM on the myocyte alone, we 
utilized myocyte-restricted gp130-/-, GP CKO mice.  These mice are globally 
IL-6 sufficient, but lack IL-6 signaling to the myocyte alone, creating a 
unique tool to study myocyte functions in vivo. 
Using these mice, in Chapter 3 we demonstrated that the detrimental action 
of IL-6 in DCM development requires IL-6-mediated signaling in the 
myocyte.  GP CKO mice are completely protected from DCM development.  
These mice have been extensively characterized; their hearts are 
developmentally normal, and have normal heart function [158, 172, 173].  We 
showed that over 36 weeks time GP CKO mice have normal heart function as 
compared with WT BALB/c mice.  These mice are also susceptible to EAM, as 
they develop disease comparable to WT.  However, despite their 
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unremarkable naïve phenotype, GP CKO mice are completely resistant to 
DCM. 
We then sought to determine how IL-6 acted directly on the myocyte.  We 
hypothesized that IL-6 directly affected the contractile function of the cell 
because IL-6 is one of the few cytokines that is known to act on myocytes.  We 
also investigated the alternative hypothesis that inflammatory cells 
infiltrating the GP CKO hearts were involved, indirectly leading to the DCM 
protection.  We also considered the possibility that fibrotic markers changed 
during earlier times during EAM than we had previously studied.  To test 
these alternatives, we investigated the profile of immune infiltrating 
populations at day 21 in WT BALB/c and GP CKO hearts, finding no 
differences in proportion of innate and adaptive immune cells, including 
comparable proportion of Th1 and Th17 cells.  We then interrogated markers 
of fibrosis by functional protein and mRNA levels at both day 14 and 21 of 
EAM.  Again, there were no differences in fibrosis, lending further evidence 
to the role of IL-6 directly on the myocyte.  After accepting the null 
hypothesis for both alternatives, we investigated changes to the myocyte 
itself. 
By studying myocytes from GP CKO mice, we demonstrated that IL-6 
signaling on the myocyte during DCM induces changes in the expression of 
proteins related to myocyte function.  We examined 3 proteins known to 
relate to myocyte function, SERCA2, ANP and BNP. SERCA2 is a 
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sarcoendoplasmic reticulum calcium transport ATPase-2. SERCA2 is the 
heart isoform within SERCA proteins.  We focused on this protein because it 
is required for myocyte excitation and contraction and its expression is 
known to be decreased in patients with heart failure [176]. Additionally, 
SERCA gene transfer has been experimentally shown to restore contractile 
function in failing hearts [190].  SERCA2 is a direct protein indicator of how 
well the myocyte is functioning, as decreases in SERCA2 levels mean less 
contractility. ANP and BNP are released from myocytes in response to 
mechanical stress and levels increase in response to changes in heart filing 
pressures [181]. Additionally, the release of ANP and BNP is increased in 
patients with heart failure [183]. ANP and BNP are both protective for the 
heart; they are released in order to return the myocyte to normal function 
[183].  However, their release is also indicative of stress and damage to the 
myocyte and therefore an indirect measure of myocyte dysfunction.  By 
measuring these 3 proteins, 1 direct indicator of function, SERCA2, and 2 
indirect indicators, ANP and BNP, we show that IL-6 alters myocyte 
function.  Hearts from GP CKO mice, protected from DCM, had more 
SERCA2 and less ANP and BNP levels in the heart as analyzed by western 
blot of heart homogenate.  Thus in WT-BALB/c hearts, IL-6 decreases 
SERCA2 expression in the myocyte and contractility, while increasing the 
expression of ANP and BNP, increasing myocyte stress. This result 
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establishes that the pathogenesis of IL-6 in DCM can be attributed in part to 
signaling on the myocyte leading to loss of cardiac function.   
4.3.2 A model of IL-6 in EAM and DCM 
In summary, we show a dual role of IL-6 in myocarditis. First it induces an 
appropriate innate response during the priming phase of EAM, then drives 
the progression of established EAM to DCM through IL-6 signaling-mediated 
loss of myocyte function. 
Initially, IL-6 is produced in response to an inflammation-inducing insult, in 
our case CFA, and induces local responses which in turn leads to changes in 
the activation of local dendritic cells and the induction of cells in the draining 
lymph nodes to produce of CCL21. The induction of IL-6 is critical for 
eventual heart involvement in EAM as adjuvants that do not induce 
sufficient IL-6, such as IFA, do not induce EAM.  The requirement for IL-6 in 
disease induction is limited to these initial reactions and is not needed 
further for EAM. 
Once EAM is established, the second role of IL-6 is driving the disease from 
cardiac inflammation to heart failure.  Chronically IL-6 acts upon the 
myocyte resulting in the loss of heart function and ultimately DCM. As IL-6 
is required to signal in trans to myocytes because they do not express the 
membrane-bound IL-6R, these experiments present a possible therapeutic 
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target for preserving heart function in patients at risk of myocarditis-
associated DCM.  
4.4 IL-6 signaling in the heart: From acute and protective to chronic 
and pathogenic  
Classically IL-6 is considered to be a proinflammatory cytokine.  When 
homeostasis is disturbed within a host, IL-6 is elevated and induces 
protective responses determined by the nature of the insult.  IL-6 can 
activate immune cells, direct immune cell trafficking, signal protective 
responses in local tissue, initiate the acute phase response or contribute to 
wound healing.  In Chapter 2 we show how IL-6 is vital in directing the local 
response to immunization in the draining lymph node, which is ultimately 
required for eventual T-cell mediated responses in the heart.  
These differing actions of IL-6 are all consequences of its basic biology (see 
Chapter 1).  During an acute response IL-6 can enhance protective responses 
by increasing immune infiltration and enhancing wound repair.  In the longer 
term, these actions of IL-6 can lead to inflammatory and fibrotic disorders.  
The heart is a tissue where this duality is dramatically illustrated.  Studies 
from MI show how short-term IL-6 signaling can protect and preserve the 
heart tissue in response to acute damage, whereas long term IL-6 signaling 
or over-production plays a causal role in cardiovascular disease.  In Chapter 3 
we demonstrate how chronically elevated IL-6 levels induce heart failure 
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post-EAM and how knowledge of this process could be a target for 
intervention. 
4.5 Translational opportunities 
The identification of the unique nature of IL-6 signaling, which occurs 
through both classical, membrane-bound signaling and through signaling in 
trans, with a soluble form of the IL-6R, has created the opportunity for 
therapeutic intervention.  Blocking all IL-6 signaling has severe 
consequences as IL-6 serves many vital functions. Anti-IL6 treatment is 
currently reserved only for severe cases of RA [116].  Having a method to only 
block the specifically pathogenic signals of IL-6 is an exciting avenue of 
future research.  The current use of the available IL-6R antibody, which 
targets both classical and trans signaling, is limited, as tocilizumab is given 
monthly by intravenous (IV) infusion.  However, many current animal 
studies aim to design more specific inhibitors, through the use of a soluble 
gp130 decoy, sgp130Fc, which inhibits only trans-signaling [195].  The 
research presented in this dissertation shows how patients with myocarditis 
may benefit from therapeutic agents such as sgp130Fc, which can prevent 
loss of myocyte function from chronic IL-6 signaling without globally 
suppressing immune responses. 
4.6 Outstanding Questions and Future Research 
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Chapter 2 implicates dendritic cell changes in the response to adjuvant.  
Additionally, lymph node tissue was shown to upregulate DC trafficking 
markers.  What remains to be answered is whether IL-6 is required for the 
appropriate migration alone or if IL-6 signaling to DCs affects DC 
presentation to T cells.  Knowing how IL-6 alters DC function could be a way 
to fine-tune innate cell responses during immunization.   
Chapter 3 elucidates how IL-6 signaling to myocytes drives progression to 
heart failure.  Still to be answered is the cellular source of that IL-6 in the 
heart and whether systemic IL-6 levels, which correlate to disease 
progression, reflect the local production of IL-6.  The results presented in 
Chapter 3 strongly suggest soluble-IL-6 signaling is a potential therapeutic 
target, therefore understanding the source and global IL-6 levels could inform 
treatment options.  Global IL-6 signaling suppression blocks the protective 
and pathogenic outcomes of IL-6, therefore knowing how to target the local 
heart-specific IL-6 signaling could minimize the risks associated with 




Figure 4.1. The dual role of IL-6 in priming EAM and in driving DCM 
1. IL-6 is initially required for the increase of DC MHCII expression and DC 
CCR7 expression, as well as the increased of CCL21 expression by the 
draining lymph node in order for the eventual T-cell involvement driving 
EAM. 
2. IL-6 is required for the progression of EAM to DCM by it’s action on the 
myocyte.  IL-6 decreases SERCA2 expression, increases ANP and BNP 
expression and depresses myocyte function leading to DCM.  
105 
 
Figure 4.2. Therapeutic targets of chronic IL-6 signaling 
IL-6 signaling can be blocked using antibodies.  Antibodies to the IL-6R block 
both classical and trans signaling of IL-6 because the antibody will bind to 
the soluble or membrane-associated form of the receptor and block 
subsequent signaling.  Alternatively, trans signaling can be blocked in 
isolation using a decoy gp130 receptor, sgp130Fc.  This targets trans 
signaling alone because the soluble IL-6R bound with IL-6 is the complex 
which binds with sgp130Fc, thus isolating sIL-6R mediated, trans, signaling.  
Using either anti-IL6R antibodies of sgp130Fc blockade, the pathogenic 
signaling of IL-6 is inhibited, however, sgp130Fc spares the classical IL-6 
signaling, which is not associated with heart failure. 
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